System and method for electrically ablating tissue of a patient

Information

  • Patent Grant
  • 11931096
  • Patent Number
    11,931,096
  • Date Filed
    Monday, June 14, 2021
    2 years ago
  • Date Issued
    Tuesday, March 19, 2024
    a month ago
Abstract
System for electrically ablating tissue of a patient through a plurality of electrodes includes a memory, a processor and a treatment control module stored in the memory and executable by the processor. The treatment control module generates an estimated treatment region based on the number of electrical pulses to be applied.
Description
FIELD OF THE INVENTION

The present invention relates to a control system for controlling a medical treatment device. More particularly, the present application relates to a system and method for electrically ablating tissue of a patient.


BACKGROUND OF THE INVENTION

Devices for delivering therapeutic energy such as an ablation device using irreversible electroporation (IRE) include a pulse generator and one or more electrodes coupled to the generator. The pulse generator delivers the therapeutic energy to a targeted tissue through the electrodes, thereby causing ablation of the tissue.


Once a target treatment area/region is located within a patient, the electrodes of the device are placed in such a way as to create a treatment zone that surrounds the target treatment region.


Prior to treatment, a treatment planning system is used to generate an estimated treatment region that completely covers the target treatment region. The estimated region is used by a physician to plan where to place the electrodes in the patient.


This can be effective when the target area is relatively small, e.g., less than 2 cm in length. However, when the target area is much larger, e.g., larger than 3 cm in length, the physician is forced to use a large number of electrodes, e.g., 4 or more electrodes. This makes accurately placing the electrodes much more difficult as moving one electrode affects the spacing from all other electrodes.


Alternatively, the large target area can be divided into two or more smaller areas and the treatment procedure for one area can be repeated to cover the other divided areas. However, this makes the entire treatment procedure much longer. The longer procedure makes it riskier for the patient since the patient would have to stay on an operating table much longer with an exposed body portion to be treated. The longer procedure also makes the procedure more expensive.


Therefore, it would be desirable to provide a system and method for electrically ablating tissue of a patient more safely and efficiently.


SUMMARY OF THE DISCLOSURE

According to one aspect of the invention, a system for electrically ablating tissue of a patient through a plurality of electrodes is provided. The system includes a memory, a processor and a treatment control module stored in the memory and executable by the processor. The treatment control module generates an estimated treatment region by taking into account the relationship between the ablation size and the number of pulses to be applied. This allows treatment of relatively large target ablation regions more efficiently and accurately.


According to another aspect of the invention, a method of electrically ablating tissue of a patient through a plurality of electrodes is provided. The method includes receiving positions of a plurality of electrodes and generating an estimated treatment region based on the received electrode positions and the number of pulses to be applied.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates several components of a medical treatment system to treat a patient according to the present invention.



FIG. 2 is a schematic diagram of a treatment control computer of the present invention.



FIG. 3 is a screen shot of an “Information” screen of a treatment control module showing various input boxes.



FIG. 4 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the four probe array and an example of the general shape of the treatment zone that can be generated by a four probe array.



FIG. 5 is a screen shot of a “Probe Placement Process” screen of the treatment control module.



FIG. 6 illustrates an example of a three probe array defining three individual treatment zones, which combine to form a combined treatment region.



FIG. 7 illustrates details of the generator shown in FIG. 1.



FIG. 8 is a graph illustrating the relationship of the number of pulses delivered and the size of the actual ablation region according to the present invention.



FIG. 9 illustrates ablation regions of varying sizes according to the number of pulses delivered according to the present invention.





DETAILED DESCRIPTION OF INVENTION

Throughout the present teachings, any and all of the one, two, or more features and/or components disclosed or suggested herein, explicitly or implicitly, may be practiced and/or implemented in any combinations of two, three, or more thereof, whenever and wherever appropriate as understood by one of ordinary skill in the art. The various features and/or components disclosed herein are all illustrative for the underlying concepts, and thus are non-limiting to their actual descriptions. Any means for achieving substantially the same functions are considered as foreseeable alternatives and equivalents, and are thus fully described in writing and fully enabled. The various examples, illustrations, and embodiments described herein are by no means, in any degree or extent, limiting the broadest scopes of the claimed inventions presented herein or in any future applications claiming priority to the instant application.


One embodiment of the present invention is illustrated in FIG. 1. One or more probes/electrodes 22 deliver therapeutic energy and are powered by a voltage pulse generator 10 that generates high voltage pulses as therapeutic energy such as pulses capable of irreversibly electroporating the tissue cells. In the embodiment shown, the voltage pulse generator 10 includes six separate receptacles for receiving up to six individual probes 22 which are adapted to be plugged into the respective receptacle. The receptacles are each labeled with a number in consecutive order. In other embodiments, the voltage pulse generator can have any number of receptacles for receiving more or less than six probes.


In the embodiment shown, each probe 22 includes either a monopolar electrode or bipolar electrodes having two electrodes separated by an insulating sleeve. In one embodiment, if the probe includes a monopolar electrode, the amount of exposure of the active portion of the electrode can be adjusted by retracting or advancing an insulating sleeve relative to the electrode. See, for example, U.S. Pat. No. 7,344,533, which is incorporated by reference herein. The generator 10 is connected to a treatment control computer 40 having input devices such as keyboard 12 and a pointing device 14, and an output device such as a display device 11 for viewing an image of a target treatment region such as a lesion 300 surrounded by a safety margin 301. The pulse generator 10 is used to treat a lesion 300 inside a patient 15. An imaging device 30 includes a monitor 31 for viewing the lesion 300 inside the patient 15 in real time. Examples of imaging devices 30 include ultrasonic, CT, MRI and fluoroscopic devices as are known in the art.


The present invention includes computer software (treatment control module 54) which assists a user to plan for, execute, and review the results of a medical treatment procedure, as will be discussed in more detail below. For example, the treatment control module 54 assists a user to plan for a medical treatment procedure by enabling a user to more accurately position each of the probes 22 of the pulse generator 10 in relation to the lesion 300 in a way that will generate the most effective treatment zone. The treatment control module 54 can display the anticipated treatment zone based on the position of the probes and the treatment parameters. The treatment control module 54 can display the progress of the treatment in real time and can display the results of the treatment procedure after it is completed. This information can be used to determine whether the treatment was successful and whether it is necessary to re-treat the patient.


For purposes of this application, the terms “code”, “software”, “program”, “application”, “software code”, “software module”, “module” and “software program” are used interchangeably to mean software instructions that are executable by a processor.


The “user” can be a physician or other medical professional. The treatment control module 54 executed by a processor outputs various data including text and graphical data to the monitor 11 associated with the generator 10.


Referring now to FIG. 2, the treatment control computer 40 of the present invention manages planning of treatment for a patient. The computer 40 is connected to the communication link 52 through an I/O interface 42 such as a USB (universal serial bus) interface, which receives information from and sends information over the communication link 52 to the voltage generator 10. The computer 40 includes memory storage 44 such as RAM, processor (CPU) 46, program storage 48 such as ROM or EEPROM, and data storage 50 such as a hard disk, all commonly connected to each other through a bus 53. The program storage 48 stores, among others, a treatment control module 54 which includes a user interface module that interacts with the user in planning for, executing and reviewing the result of a treatment. Any of the software program modules in the program storage 48 and data from the data storage 50 can be transferred to the memory 44 as needed and is executed by the CPU 46.


In one embodiment, the computer 40 is built into the voltage generator 10. In another embodiment, the computer 40 is a separate unit which is connected to the voltage generator through the communication link 52. In a preferred embodiment, the communication link 52 is a USB link.


In one embodiment, the imaging device 30 is a stand alone device which is not connected to the computer 40. In the embodiment as shown in FIG. 1, the computer 40 is connected to the imaging device 30 through a communication link 53. As shown, the communication link 53 is a USB link. In this embodiment, the computer can determine the size and orientation of the lesion 300 by analyzing the data such as the image data received from the imaging device 30, and the computer 40 can display this information on the monitor 11. In this embodiment, the lesion image generated by the imaging device 30 can be directly displayed on the grid 200 of the monitor 11 of the computer running the treatment control module 54. This embodiment would provide an accurate representation of the lesion image on the grid 200, and may eliminate the step of manually inputting the dimensions of the lesion in order to create the lesion image on the grid 200. This embodiment would also be useful to provide an accurate representation of the lesion image if the lesion has an irregular shape.


The basic functionality of the computer software (treatment control module 54) will now be discussed in relation to the following example.


It should be noted that the software can be used independently of the generator 10. For example, the user can plan the treatment in a different computer as will be explained below and then save the treatment parameters to an external memory device, such as a USB flash drive (not shown). The data from the memory device relating to the treatment parameters can then be downloaded into the computer 40 to be used with the generator 10 for treatment.


After the treatment control module 54 is initialized, it displays an “Information” screen with various input boxes as shown in FIG. 3. A keyboard or other input device 12, together with a mouse or other pointing device 14 (see FIG. 1) are used to input the data. Any data that is inputted into the input boxes can be saved into internal or external memory along with a record of the treatment as described below for future reference. The basic patient information can be inputted, such as a patient ID number in input box 100, the name of the patient in input box 101, and the age of the patient in input box 102. The user can enter clinical data, such as the clinical indication of the treatment in input box 114. The date of the procedure is automatically displayed at 111 or can be inputted by the user in another embodiment. The user can enter other case information such as the name of the physician in input box 112 and any specific case notes in input box 113.


The dimensions of the lesion 300 are determined from viewing it on the monitor 31 of the imaging device 30 (see FIG. 1) such as an ultrasonic imaging device and using known methods to calculate the dimensions from the image generated from the imaging device 31. The dimensions of the lesion 300 (length at input box 103, width at input box 104, and depth at input box 105) are inputted into the program. A safety margin is selected at input box 106 which will surround the entire lesion 300 in three dimensions. According to the size of the safety margin that is selected, a target treatment region is automatically calculated and is displayed in boxes 107, 108, and 109 as shown. In one embodiment, the safety margin value may be set to zero. For example, when treating a benign tumor, a safety margin may not be necessary.


In the embodiment shown in FIG. 3, the user has indicated that the lesion that will be treated has a length of 2 cm, width of 1 cm and a depth of 1 cm. With a user specified margin of 1 cm (which is a default margin setting), the target treatment region has a length of 4 cm, width of 3 cm and a depth of 3 cm.


The user can select the “ECG synchronization” option by clicking the circle in the box 110 in order to synchronize the pulses with an electrocardiogram (ECG) device, if such a device is being used during the procedure. The other options available for treatment that are included in box 110 can include an option for “90 PPM” (pulses per minute) or “240 PPM”. The user should select at least one of the three options provided in box 110. After all of the necessary data has been inputted, the user clicks on the “Next” button with a pointing device 14 to proceed to the next screen described below.


Further regarding the ECG synchronization option, if this circle is selected in window 110, the treatment control module 54 will test this functionality to verify that the system is working properly. The treatment control module 54 can automatically detect whether an error has occurred during the testing phase of the ECG feature. The detectable errors include, but are not limited to, “no signal” (such as no pulses for 3.5 seconds) and “noisy” (such as pulses occurring at a rate greater than 120 beats per minute for at least 3.5 seconds).


The treatment control module 54 can synchronize energy release with cardiac rhythm by analyzing cardiac output such as electrocardiogram results (or other cardiac function output) and sending synchronization signals to a controller of the pulse generator 10. The control module 54 is also capable of generating internal flags such as a synchronization problem flag and a synchronization condition flag to indicate to users on a graphic user interface a synchronization status, so that energy pulse delivery can be synchronized with the cardiac rhythm for each beat (in real-time) or aborted as necessary for patient safety and treatment efficiency.


Specifically, the control module 54 synchronizes energy pulses such as IRE (irreversible electroporation) pulses with a specific portion of the cardiac rhythm. The module uses the R-wave of the heartbeat and generates a control signal to the pulse generator 10 indicating that this portion of the heartbeat is optimal for release of IRE pulses. For clarity, the S wave would be an optimal time for delivery of an energy pulse, but due to the fact that the S wave ends nebulously in some cases, the R wave is used as an indicator to start timing of energy release.


More specifically, the synchronization feature of the control module 54 allows for monitoring of heart signals so as to ensure that changes, maladies, and other alterations associated with the heartbeat are coordinated such that pulses from the pulse generator 10 are released at the proper time, and that if the heartbeat is out of its normal rhythm, that the release of energy is either altered or aborted.


Next, the user can select the number of probes that the user believes will be necessary to produce a treatment zone which will adequately cover the lesion 300 and any safety margin 301. The selection is made by clicking the circle next to each type of device, as shown in the “Probe Selection” screen, illustrated in FIG. 4.


In one embodiment, a “Probes Selection Status” box 199 identifies which of the receptacles, if any, on the generator 10 have been connected to a probe by displaying the phrase “Connected” or the like next to the corresponding probe number. In one embodiment, each receptacle includes an RFID device and a connector for each probe which connects to the receptacle and includes a compatible RFID device, so that the treatment control module 54 can detect whether or not an authorized probe has been connected to the receptacle on the generator 10 by detecting a connection of the compatible RFID devices. If an authorized probe is not connected to a receptacle on the generator, the phrase “Not Connected” or the like will appear next to the probe number. In addition, the color of each probe shown in the “Probes Selection Status” box 199 can be used to indicate whether or not each receptacle on the generator is connected to a compatible probe. This feature allows the user to verify that the requisite number of probes are properly connected to the generator 10 before selecting a probe type for the treatment procedure. For example, if the treatment control module 54 detects a problem with the probe connection status (e.g. selecting a three probe array when only two probes are connected to the generator), it can notify the user by displaying an error message.


The user can select which of the connected probes will be used to perform the treatment procedure, by clicking on the box next to the selected probes in the “Probes Selection Status” box 199. By default the treatment control module 54 will automatically select probes in ascending numerical order, as they are labeled.


Referring to FIG. 4, circle 150 is used to select a four probe array. FIG. 4 illustrates a side view 151 and top view 152 of the four probe array and an example of the general shape of the treatment zone that can be generated by a four probe array. In the illustrated example, the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the four probes are equally spaced from each other by 15 mm, as measured at four places (PLCS) along the perimeter.



FIG. 5 illustrates a “Probe Placement Process” screen of one aspect of the invention. The screen illustrated by FIG. 5 shows a lesion 300 according to the dimensions which were inputted on the “Information” screen (see FIG. 3) along with a safety margin 301, if any, that was previously inputted. In the example depicted in FIG. 5, the lesion 300 has a length of 2.0 cm and a width of 1.0 cm, and the device selected on the “Probe Selection” screen (see FIG. 4) is a four probe array. The lesion 300 is displayed near the center of an x-y grid 200 with the distance between two adjacent grid lines representing 1 mm. Each of the four probes 201, 202, 203, 204 is displayed in the grid 200 and each probe can be manually positioned within the grid by clicking and dragging the probe with the pointing device 14. Two fiducials 208, 209 labeled “A” and “B”, respectively, are also displayed on the grid 200 and are used as a point of reference or a measure as will be described below.


The amount of longitudinal exposure of the active electrode portion for each probe that has already been manually adjusted by the user as explained above can be manually inputted in input box 210, which can be selected by the user according to the depth (z) of the lesion. In this way, the treatment control module 54 can generate an estimated treatment zone according to the treatment parameters, and locations and depths of the probes. In one embodiment, a second x-z grid is displayed on the monitor 11 of the computer running the treatment control module 54. In one embodiment, the treatment control module 54 can automatically calculate preferred values for the amount of longitudinal exposure of the active electrode portions based on the size and shape of the lesion. The depth (z) of the electric field image can be calculated analytically or with interpolation and displayed on the x-z grid. Because the distribution of the electric field (i.e., expected treatment region) between two monopolar electrodes may “dip in” along the boundary line (e.g., a peanut shaped treatment region due to large spacing between the two electrodes where the width of the region is smaller in the middle; see for example region 305 in FIG. 9) depending on the electrode location and the applied voltage, it is beneficial to have an x-z grid included on the monitor. For example, if this “dip” of the boundary line travels into, rather than surround/cover, the lesion region, then the targeted region may not be fully treated. As a default to ensure treatment of the entire lesion region, the probe depth placement and the exposure length may be set unnecessarily higher to ensure erring on the safe side. However, this will potentially treat a much larger volume than needed, killing healthy surrounding tissue, which can be an issue when treating sensitive tissues such as the pancreas, brain, etc. By optimizing the treatment depth (z) together with the width (x) and height (y), this effect may be reduced, further enhancing procedural protocol and clinical outcome.


The probe dock status is indicated in box 210, by indicating if the probes are “docked” or “undocked”. The “UnDock Probes” button allows the user to “unplug” the probes from the generator while the “Probe Placement Process” screen is displayed without causing error messages. In normal operation, the user plugs the probes into the generator on the “Probe Selection” screen, and then the probes are “authorized” as being compatible probes according to the RFID devices, as discussed above. When the user proceeds to the “Probe Placement Process” screen, the software requires that all the selected probes remain plugged into the generator, or else the software will display an error message (e.g. “Probe #2 unplugged”, etc.), and will also force the user back to the “Probe Selection” screen. However, sometimes doctors may want to perform another scan of the lesion or perform some other procedure while leaving the probes inserted in the patient. But, if the procedure cannot be performed near the generator, the probes are unplugged from the generator. If the user selects the “UnDock Probes” button, this will allow the probes to be unplugged from the generator without causing an error message. Then, after the user has performed the other procedure that was required, he can re-attach the probes to the generator, and then select “Dock Probes” in input box 210. In this way, the user will not receive any error messages while the “Probe Placement Process” screen is displayed.


There is a default electric field density setting (Volts/cm) which is shown in input box 211. In the example, the default setting is 1500 Volts/cm. This number represents the electric field density that the user believes is needed to effectively treat the cells, e.g., ablate the tissue cells. For example, 1500 Volts/cm is an electric field density that is needed to irreversibly electroporate the tissue cells. Based on the number selected in input box 211, the treatment control module 54 automatically adjusts the voltage (treatment energy level) applied between the electrodes, as shown in column 222.


Box 280 allows a user to select between two different Volts/cm types, namely “Linear” or “Non-Linear Lookup”.


The default Volts/cm setting is “Linear”, in which case the Voltage that is applied between a given pair of electrodes, as shown in column 222, is determined by the following formula:

Voltage=xd,  (1)

    • where x=the electric field density setting (Volts/cm) shown in column 225, which is based on the value from box 211, and
    • where d=the distance (cm) between the given pair of electrodes shown in column 226.


      Therefore, when “Linear” is selected, the Voltage that is applied between a given pair of electrodes is directly proportional to the Distance between the given electrode pair in a linear relationship.


If the user selects “Non-Linear Lookup” in box 280, then the Voltage that is applied between the given pair of electrodes will be similar to the Voltage values for a “Linear” selection when a pair of electrodes are closely spaced together (e.g. within about 1 cm). However, as a pair of given electrodes are spaced farther from one another, a “Non-Linear Lookup” will produce lower Voltages between the given pair of electrodes as compared to the Voltage values for a “Linear” selection at any given distance. The “Non-Linear Lookup” feature is particularly useful for reducing “popping” during treatment. “Popping” refers to an audible popping noise that sometimes occurs, which is believed to be caused by a plasma discharge from high voltage gradients at the tip of the electrodes. The “Non-Linear Lookup” feature can also minimize any swelling of the tissue that might occur as a result of a treatment. The Voltage values used for the “Non-Linear Lookup” selection can be pre-determined based on animal experiments and other research. In one embodiment, different tissue types can each have their own “Non-Linear Lookup” table. In the example shown, the tissue being treated is prostate tissue.


The details of the treatment parameters are displayed in window 270. The firing (switching) sequence between probes is listed automatically in window 270. In the example, the firing sequence involves six steps beginning with between probes 1 and 2, then probes 1 and 3, then probes 2 and 3, then probes 2 and 4, then probes 3 and 4, and then probes 4 and 1. As shown, the polarity of each of the probes may switch from negative to positive according to step of the firing sequence. Column 220 displays which probe is the positive probe (according to a number assigned to each probe) for each step. Column 221 displays which probe is the negative probe (according to a number assigned to each probe) for each step. Column 222 displays the actual voltage generated between each probe during each step of the firing sequence. In the example, the maximum voltage that can be generated between probes is limited by the capabilities of the generator 10, which in the example is limited to a maximum of 3000 Volts. Column 223 displays the length of each pulse that is generated between probes during each respective step of the firing sequence. In the example, the pulse length is predetermined and is the same for each respective step, and is set at 100 microseconds. Column 224 displays the number of pulses that is generated during each respective step of the firing sequence. In the example, the number of pulses is predetermined and is the same for each respective step, and is set at 90 pulses which are applied in a set of 10 pulses at a time. Column 225 displays the setting for Volts/cm according to the value selected at input box 211. Column 226 displays the actual distance between the electrodes (measured in cm), which is automatically calculated according to the placement of each probe in the grid 200.


The treatment control module 54 can be programmed to calculate and display the area of the combined treatment regions on the grid 200 by several different methods.


Each method determines a boundary line surrounding a treatment zone that is created between a pair of electrodes. By combining a plurality of treatment zones with each treatment zone being defined by a pair of electrodes, a combined treatment region can be displayed on the x-y grid. FIG. 6 illustrates three electrodes 201 (E1), 202 (E2), 203 (E3) defining three individual treatment zones 311, 312, 313, which combine to form a combined treatment region 315 which is shown with hatched lines.


As discussed above, the monitor can further include an x-z grid to illustrate the depth of the lesion and the shape of the treatment region. The shape of the treatment zone in the x-z grid will vary according to the selected amounts of electrode exposure for each probe and can be determined by one or more methods.


In one embodiment, the treatment boundary line that is created between two points on the x-y grid can be rotated about an axis joining the two points in order to generate the treatment region boundary line on the x-z grid. In this embodiment, several points may be selected along the exposed length of the active electrode portion for each probe at various depths (z). A three-dimensional combined treatment region can then be generated by determining the boundary line on the x-y grid between each individual pair of points and then rotating the boundary line along the axis joining each pair of points. The resulting boundary lines can be combined to create a three dimensional image that is displayed on the monitor.


The following is an alternate method for determining a boundary line on the x-z grid, thereby determining a three dimensional treatment region. This example describes a two probe array with the probes being inserted in a parallel relationship and with the probes having the same amount of exposed portions of the electrode. In this example, the exposed portions of each probe start at the same “uppermost” depth (z) and end at the same “lowermost” depth (z). First, a treatment zone boundary line is created in the x-y plane at the uppermost depth (z). Next, the treatment zone boundary line is repeatedly created stepwise for all subsequently lower depths (z), preferably evenly spaced, until the lowermost depth (z) is reached. The result is a 3-D volume (stacked set of treatment zone boundary lines) having a flat top surface and a flat bottom surface. Next, two new focus points are selected, with the first focus point positioned midway between the probe positions in the x-y grid and near the uppermost depth (z) of the exposed electrode. The second focus point is also positioned midway between the probe positions in the x-y grid, but near the lowermost depth (z) of the exposed electrode. Next, a treatment zone boundary line is created in the x-z grid using one of the methods described earlier. The actual placement of each focus point may be closer together, namely, not positioned in the uppermost and lowermost x-y planes defined by the exposed portions. The placement of each focus point should be selected so that the treatment zone boundary line that is created in the x-z grid closely matches the treatment zone boundary lines that were created in the uppermost and lowermost x-y grids. Next, the treatment zone boundary line that was created in the x-z grid according to the two focus points is rotated about the axis joining the two focus points. This creates the shapes for the upper and lower 3-D volumes which are added to the flat top surface and the flat bottom surface described above.


The above methods can be applied by persons of ordinary skill in the art to create 3-D treatment zones between exposed portions of electrodes even when the probes are not parallel to each other and even when the amount of the exposed portion varies with each probe.


Furthermore, there are situations where it is advantageous to show multiple boundary zones as a result of a therapy. For example, indicating which regimes undergo no change, reversible electroporation, irreversible electroporation, and conventional thermal damage is possible in accordance with the present invention. In addition, it is possible to output the entire distribution rather than just delineating boundaries.


It has been shown repeatedly in the literature that tissue properties are highly variable between tissue types, between individuals, and even within an individual. These changes may result from differences in body fat composition, hydration levels, and hormone cycles. Due to the large dependence of IRE (irreversible electroporation) treatments on tissue conductivity, it is imperative to have accurate values. Therefore, to obtain viable conductivity values prior to treatment, a low amplitude voltage pulse is used between the electrode conductors and the resultant impedance/conductance is measured as a way to determine pertinent tissue property data such as the predicted current. The value determined may then be implemented when assessing field strength and treatment protocol in real time. For example, the resulting impedance or predicted current can be used to set the default electric field density.


One method of generating an estimated treatment region between a pair of treatment electrodes is a numerical model based method involving finite element analysis (FEA). For example, U.S. Patent Application Publication No. 2007/0043345, which is hereby incorporated by reference, discloses using FEA models to generate treatment zones between a pair of electrodes (the calculations were performed using MATLAB's finite element solver, Femlab v2.2 (The MathWorks, Inc. Natick, Mass.)).


Most engineering problems can be solved by breaking the system into cells where each corner of the cell or mesh is a node. FEA is used to relate each node to each of the other nodes by applying sets of partial differential equations. This type of a system can be coded by scratch, but most people use one of many commercial FEA programs that automatically define the mesh and create the equations given the model geometry and boundary conditions. Some FEA programs only work in one area of engineering, for example, heat transfer and others are known as multiphysics. These systems can convert electricity to heat and can be used for studying the relationships between different types of energy.


Typically the FEA mesh is not homogeneous and areas of transition have increased mesh density. The time and resources (memory) required to solve the FEA problem are proportional to the number of nodes, so it is generally unwise to have a uniformly small mesh over the entire model. If possible, FEA users also try to limit the analysis to 2D problems and/or use planes of symmetry to limit the size of the model being considered because even a modest 2D model often requires 30 minutes to several hours to run. By comparison, a 3D Model usually takes several hours to several days to run. A complicated model like a weather system or a crash simulation may take a super computer several days to complete.


Depending on the complexity of the FEA models that are required, the purchase price of the FEA modeling software can cost several thousand dollars for a low end system to $30 k for a non linear multiphysics system. The systems that model the weather are custom made and cost tens of millions of dollars.


In one example, the steps which are required for generating a treatment zone between a pair of treatment probes using finite element analysis include: (1) creating the geometry of interest (e.g., a plane of tissue with two circular electrodes); (2) defining the materials involved (e.g., tissue, metal); (3) defining the boundary conditions (e.g., Initial voltage, Initial temperature); (4) defining the system load (e.g., change the voltage of the electrodes to 3,000V); (5) determining the type of solver that will be used; (6) determining whether to use a time response or steady state solution; (7) running the model and wait for the analysis to finish; and (8) displaying the results.


Using FEA, however, may not be practical for use in calculating and displaying in real time a treatment zone that is created between a pair of treatment probes in accordance with the present invention because of the time required to run these types of analyses. For the present invention, the system should allow a user to experiment with probe placement and should calculate a new treatment zone in less than a few seconds. Accordingly, the FEA model is not appropriate for such use and it would be desirable to find an analytic solution (closed form solution), which can calculate the treatment zones with only simple equations, but which closely approximate the solutions from a numerical model analysis such as the finite element analysis. The closed loop solutions should preferably generate the treatment zone calculation in a fraction of a second so as to allow a physician/user to experiment with probe placement in real time.


There are different closed loop (analytical model analysis) methods for estimating and displaying a treatment zone between a pair of treatment probes, which produce similar results to what would have been derived by a numerical model analysis such as FEA, but without the expense and time of performing FEA. Analytical models are mathematical models that have a closed form solution, i.e., the solution to the equations used to describe changes in a system can be expressed as a mathematical analytic function. The following method represents just one of the non-limiting examples of such alternative closed loop solutions.


In mathematics, a Cassini oval is a set (or locus) of points in the plane such that each point p on the oval bears a special relation to two other fixed points q1 and q2: the product of the distance from p to q1 and the distance from p to q2 is constant. That is, if the function dist(x,y) is defined to be the distance from a point x to a point y, then all points p on a Cassini oval satisfy the equation:

dist(q1,p)×dist(q2,p)=b2  (2)

    • where b is a constant.


The points q1 and q2 are called the foci of the oval.


Suppose q1 is the point (a,0), and q2 is the point (−a,0). Then the points on the curve satisfy the equation:

((x−a)2+y2)((x+a)2+y2)=b4  (3)
The Equivalent Polar Equation is:
r4−2a2r2 cos 2θ=b4−a4  (4)


The shape of the oval depends on the ratio b/a. When b/a is greater than 1, the locus is a single, connected loop. When b/a is less than 1, the locus comprises two disconnected loops. When b/a is equal to 1, the locus is a lemniscate of Bernoulli.


The Cassini equation provides a very efficient algorithm for plotting the boundary line of the treatment zone that was created between two probes on the grid 200. By taking pairs of probes for each firing sequence, the first probe is set as q1 being the point (a,0) and the second probe is set as q2 being the point (−a, 0).


The polar equation for the Cassini curve is preferably used because it provides a more efficient equation for computation. The current algorithm can work equally as well by using the Cartesian equation of the Cassini curve. By solving for r2 from eq. (4) above, the following polar equation was developed:

r2=a2 cos(2*theta)+/−sqrt(b4−a4 sin2(2*theta))  (5)

    • where a=the distance from the origin (0,0) to each probe in cm; and
    • where b is calculated from the following equation:










b
2

=


[

V


[



ln


(
a
)




(

5

9


5
.
2


8

)


+

2

3

3

9


]



(

A

6

5

0


)



]

2





(
6
)









    • where V=the Voltage (V) applied between the probes;

    • where a=the same a from eq. (5); and

    • where A=the electric field density (V/cm) that is required to ablate the desired type of tissue according to known scientific values.





As can be seen from the mathematics involved in the equation, r can be up to four separate values for each given value for theta.


Example 1

If V=2495 Volts; a=0.7 cm; and A=650 V/cm;


Then b2=1.376377

    • and then a cassini curve can be plotted by using eq. (5) above by solving for r, for each degree of theta from 0 degrees to 360 degrees.


A portion of the solutions for eq. (5) are shown in Table 1 below:

    • where M=a2 cos(2*theta); and L=sqrt(b4−a4 sin2(2*theta))















TABLE 1







Theta
r = sqrt
r = −sqrt
r = sqrt
r = −sqrt



(degrees)
(M + L)
(M + L)
(M − L)
(M − L)






















0
1.366154
−1.36615
0
0



1
1.366006
−1.36601
0
0



2
1.365562
−1.36556
0
0



3
1.364822
−1.36482
0
0



4
1.363788
−1.36379
0
0



5
1.362461
−1.36246
0
0



6
1.360843
−1.36084
0
0



7
1.358936
−1.35894
0
0



8
1.356743
−1.35674
0
0



9
1.354267
−1.35427
0
0



10
1.351512
−1.35151
0
0



11
1.348481
−1.34848
0
0



12
1.34518
−1.34518
0
0



13
1.341611
−1.34161
0
0



14
1.337782
−1.33778
0
0



15
1.333697
−1.3337
0
0










The above eq. (6) was developed according to the following analysis.


The curve from the cassini oval equation was calibrated as best as possible to the 650 V/cm contour line using two 1-mm diameter electrodes with an electrode spacing between 0.5-5 cm and an arbitrary applied voltage.


For this worksheet, q1 and q2 reference points (taken to be +/−electrodes) could be moved to locations along the x-axis to points of (±a,0). A voltage could then be selected, and an arbitrary scaling factor (“gain denominator”) would convert this voltage to the corresponding “b” used in eq. (4). The worksheet would then plot the resulting Cassini oval, which has a shape progression with applied voltage beginning as two circles around the electrodes that grow into irregular ellipses before converging into a single “peanut” shape that ultimately becomes an ellipse expanding from the original electrode locations.


The Cassini oval creates a reasonable visualization that mimics the shape of numerical results for the field distribution. In order to understand which values or levels correspond to a desired electric field of interest, a calibration involving the b4 term was necessary to develop the relationship between the analytical Cassini oval and the numerical results. This was done through a backwards calibration process defined as follows:

    • 1. A reference contour was selected to correlate the analytical and numerical solutions. This was chosen to be when b/a=1, forming a lemniscate of Bernoulli (the point where the two ellipses first connect, forming “∞”).
    • 2. A reference electric field density value was selected to be 650 V/cm.
    • 3. Numerical models were developed to mimic the x-y output from the Cassini oval for scenarios where a=±0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.25, and 2.5 cm.
    • 4. Models were solved using trial and error to determine which voltage yielded the electric field contour of 650 V/cm in the shape of a lemniscate of Bernoulli.
    • 5. The determined voltage was placed into the Cassini oval electronic worksheet for the same electrode geometry and the “gain denominator” was adjusted until the shape from the cassini oval matched that from the numerical solution.
    • 6. The determined gain denominators for all values of “a” were collected and a calibration plot was made and fitted with a logarithmic trendline of:

      Gain Denominator=595.28·ln(a)+2339;R2=0.993  (7)
    • 7. The calibration trendline function shown above was incorporated back into the Cassini Oval spreadsheet. At this point, the worksheet was capable of outputting a field contour of 650 V/cm for any electrode separation distance (±a) and applied voltage (V).
    • 8. The calibration function was then scaled to a desired electric field contour input. This allowed the analytical solution to solve for any electric field for any given a separation distance and voltage. Since the Laplace equation is linear, scaling should provide a good estimate for how other fields would look.


Table 1 incorporates all the steps above to yield a single, calibrated Cassini Oval output that analytically predicts the electric field distribution; providing a quick and simple solution for the prediction of IRE (irreversible electroporation) treatment regions that may be adjusted in real-time. The inputs are the electrode location (as a given “±a” distance from the origin along the x-axis), the applied voltage to the energized electrode, and the desired electric field to visualize. The resulting output is a contour representing a threshold where the entire area within it has been subjected to an electric field the one selected; and thus treated by IRE. It is important to remember that the analytical solution was calibrated for an electric field contour of 650 V/cm, and thus yields an accurate approximation for this value. Other field strength contours of interest still yield reasonable results that mimic the overall shape of the electric field. Overall, the analytical solution provided yields consistently good predictions for electric field strengths, and thus, treatment regions of IRE that may be used during treatment planning or analysis.


A similar algorithm for calibration can be used for a bipolar electrode.


In one example, the diameter of the probe is 0.065 cm, and the lengths of the two electrodes are respectively 0.295 cm and 0.276 cm, separated by an insulation sleeve of 0.315 cm in length. Adapting this scenario to the cassini oval presents some challenges because the distribution is now resulting from the two exposed cylinder lengths, rather than two distinct loci of points. This was solved by calibrating individual electric field contours for the same applied voltage and developing two equations that adjust the separation distance (±a) and gain denominator (GD) according to the equations:

a=710−9*E3−2*10−5*E2+0.015*E+6.1619;R2=0.9806  (8)
GD=1.0121*E+1920;R2=0.9928  (9)

    • where E is the electric field magnitude contour desired.


      These two equations may then be used to calibrate the cassini ovals into a satisfactory shape to mimic the electric field distribution, and thus treatment region accordingly.



FIG. 6 illustrates an example of how to generate a combined treatment zone according to the invention. Three electrodes 201, 202, 203 defining three individual treatment zones 311, 312, 313, combine to form a combined treatment region 315 which is shown with hatched lines. By combining a plurality of treatment zones with each treatment zone being defined by a pair of electrodes, a combined treatment region 315 can be displayed on the x-y grid.



FIG. 7 illustrates one embodiment of a pulse generator according to the present invention. A USB connection 52 carries instructions from the user computer 40 to a controller 71. The controller can be a computer similar to the computer 40 as shown in FIG. 2. The controller 71 can include a processor, ASIC (application-specific integrated circuit), microcontroller or wired logic. The controller 71 then sends the instructions to a pulse generation circuit 72. The pulse generation circuit 72 generates the pulses and sends electrical energy to the probes. In the embodiment shown, the pulses are applied one pair of electrodes at a time, and then switched to another pair using a switch 74, which is under the control of the controller 71. The switch 74 is preferably an electronic switch that switches the probe pairs based on the instructions received from the computer 40. A sensor 73 such as a sensor can sense the current or voltage between each pair of the probes in real time and communicate such information to the controller 71, which in turn, communicates the information to the computer 40. If the sensor 73 detects an abnormal condition during treatment such as a high current or low current condition, then it will communicate with the controller 71 and the computer 40 which may cause the controller to send a signal to the pulse generation circuit 72 to discontinue the pulses for that particular pair of probes.


The treatment control module 54 can further include a feature that tracks the treatment progress and provides the user with an option to automatically retreat for low or missing pulses, or over-current pulses (see discussion below). Also, if the generator stops prematurely for any reason, the treatment control module 54 can restart at the same point where it terminated, and administer the missing treatment pulses as part of the same treatment.


In other embodiments, the treatment control module 54 is able to detect certain errors during treatment, which include, but are not limited to, “charge failure”, “hardware failure”, “high current failure”, and “low current failure”.


According to the present invention, irreversible electroporation (IRE) ablation (n=81, where n is the number of IRE ablation procedures) was performed in-vivo in 22 pig livers using 2-4 IRE electrodes (18 gauge, 2 cm long tip) and a NanoKnife™ generator (AngioDynamics, Fremont, CA) as described in the IRE Treatment Application referenced above and as shown in FIGS. 1, 2 and 7. Cardiac-gated (i.e., synchronized to cardiac cycle) 100 μsec IRE pulses were applied sequentially between electrode pairs at 3,000-3,400V (one pair at a time).


Multiple variables for energy deposition and electrode configuration were studied including: inter-electrode spacing (1.5 cm-3 cm); the number of IRE pulses applied between electrode pairs (c=10, 50, & 100); and the order and number of times/cycles each electrode pair was activated.


For c=10, a sequence of delivered pulses are as follows: 10 sequential IRE pulses were delivered per electrode pair for all pairs (e.g., 10 pulses for pair 1-2, then 10 pulses for pair 2-3 and then 10 pulses for pair 3-1 for a 3-electrode array). Then the same sequence is repeated 2 to 44 times for a total number of IRE pulses delivered of 20 to 440 per electrode pair. Electrode phase (polarity) was changed after each sequence (1-2, 2-3, 3-1; 2-1, 3-2, 1-3), which reduces gas buildup near the electrodes to thereby reduce the chance of sparks. In one experiment, a total of 90 IRE pulses were delivered for each electrode pair.


For c=50, a sequence of 50 IRE pulses were delivered per electrode pair for all pairs. Then the same sequence is repeated one more time for a total number of IRE pulses delivered of 100 per electrode pair.


For c=100, a sequence of 100 sequential IRE pulses were delivered per each electrode pair. Then the same sequence is repeated one more time for a total number of IRE pulses delivered of 200 per electrode pair.


Between two pulses, two electrode pairs and two sequences, there is a waiting (delay) period. The reasons for the waiting period are to dissipate any thermal buildup in the tissue cells, especially around the electrodes where the current density is highest, and to increase the ablation zone.


Preferably, the generator 10 inserts a time delay between two pulses (inter-pulse delay) of at least 250 ms (milliseconds) and at most 15 seconds, and more preferably at least 1 second and at most 8 seconds. At greater than 8 seconds, the ablation zone does not increase and actually may help to decrease it.


Preferably, the generator 10 inserts a time delay of 5 seconds to 10 minutes between electrode pairs (inter-pair delay) within a sequence. Preferably, the generator inserts a time delay of 5 seconds to 20 minutes between two sequences (inter-sequence delay).


With a single IRE pulse, the cells try to close the holes/pores created in the membrane within a fraction of a second. By applying multiple pulses with inter-pulse, inter-pair and inter-sequence delays, it is believed that the cells' attempt to repeatedly close the holes exhaust their ability to close them, which thereby increases the ablation zone.


Ablations were performed under ultrasound guidance. Dimensions of resultant zones of treatment were measured by ultrasound 1-3 hr post-procedure and confirmed at gross and histopathology. These data and ablation times were compared and subject to statistical analysis to determine optimal pulse parameters.


Although the experiments involved 10, 50 and 100 pulses in a sequence, the general inventive concept can be expanded to include as little as 1 pulse per electrode pair in a sequence. In other words, for a 3 electrode array, a sequence of 1 IRE pulse per electrode pair is applied for all three pairs. Then, the sequence is repeated for 70 to 100 times. Preferably, the number of pulses for each electrode pair in a single sequence can vary between 1 and 280.


Currently, the NanoKnife generator is programmed to deliver a single IRE pulse per cardiac cycle if a cardiac-sync is selected. In a 3 or more multi-electrode array, more than one IRE pulse per cycle can be delivered by switching electrodes using the switch 74. For example, in a 3 electrode-array arrangement, in a single cardiac cycle, a sequence of single IRE pulse between pair 1-2, between pair 2-3 and between pair 2-3 can be applied for a total of 3 IRE pulses delivered, for example, within an R-wave of the cycle.


Alternatively, for applying 100 pulses, a sequence of 10 IRE pulses between pair 1-2, then between pair 2-3 and then between pair 2-3 can be applied for a total of 10 sets to deliver a total of 100 pulses for each electrode pair. For applying 500 pulses, a sequence of 10 IRE pulses can be sequentially applied to the 3 electrode pairs for a total of 50 sets. For applying 1000 pulses, a sequence of 10 IRE pulses can be sequentially applied to the 3 electrode pairs for a total of 100 sets.


The IRE pulses can be unipolar pulses or alternating polarity pulses such as biphasic pulses or consecutive positive and negative pulses separated by a slight time delay.


According to the experiments, the largest contiguous zones of treatment effect (6.4±0.6 cm width and length, 3.7±1.4 cm height) were achieved applying 2 cycles (sequences) of 50 IRE pulses sequentially to all electrode pairs within a 4 electrode array of 2.5 cm spacing (total time=17.5±6.7 min). For 4 electrode arrays, treatment diameter best correlated with overall time of the energy application [r2=0.71]). Greatest ablation for 3 electrode arrays (5.9±0.4 cm×5.3±0.5 cm cross-sectional area) was achieved by continuously delivering 10 pulses sequentially to each of the 3 electrode pairs for 10-12 min. For 2 electrode arrays using similar energy application strategies, ablation of only 3.9±0.5 cm length with variable width (incomplete to 2.4 cm) was achieved.


In another experiment, IRE ablation procedures were performed on porcine liver using the following parameters: 2.5 cm spacing between the electrodes, 100 μs pulses, 3 kVolts, 2 cm exposed electrodes, and 100-1000 pulses delivered. FIG. 8 is a graph illustrating the relationship of the number of pulses delivered to a pair of electrodes and the size of the actual ablation region in this experiment.


As can be seen, there is generally a positive correlation between the number of pulses (and therefore the total pulse application time) and the size of the ablation region although the rate of increase slows as more pulses are applied. For length, it varied between 4 cm and 5.7. For width, it varied between 1.5 cm and 3.3 cm. Using a curve fitting algorithm, the graph for length and width produced the following formulas:

y=1.6832*x−0.1849, where x=length in centimeter, and
y=0.3407*x−0.3381, where x=width in centimeter.


Table 2 below summarizes the experimental data in terms of the increase in size in two dimensions (area) and three dimensions (volume).















TABLE 2






Width of
Length of
2-D

3-D




ablated
ablated
ablated
%
ablated
%


# of 100
region
region
region
increase
volume
increase


μs pulses
(cm)
(cm)
(cm{circumflex over ( )}2)
in area
(cm{circumflex over ( )}3)
in volume







 100
1.5
4
 6
NA
 24
NA


 600
2.9
5.5
15.95
166%
 87.725
266%


1000
3.3
6
19.8
230%
118.8
395%









As seen above, for two dimensional regions, increasing the number of pulses from 100 to 600 and 1000 respectively produced a surprisingly large increase of 166% and 230% in ablation area. If an assumption is made that the increase in depth is similar to the increase in length, then increasing the number of pulses from 100 to 600 and 1000 respectively produces an increase of 266% and 395% in ablation volume.


Based on the above relationship between the ablation size and the number of delivered pulses, calculation of the estimated treatment region can be adjusted accordingly. For example, if the experimental data show that the shape of the treatment region increases proportionally (width, length and depth of the region), then the term b{circumflex over ( )}2 in the Cassini oval equation may be adjusted accordingly. If, however, the shape of the treatment region increases in a non-proportional manner (e.g., length increases at twice the rate as the width), then the Cassini oval equation can be modified by adding or subtracting a constant to the b{circumflex over ( )}2 term (e.g., b{circumflex over ( )}2+/−C) as well as adjusting the b{circumflex over ( )}2 term itself. Alternatively, the number of electrodes can be reduced.


Aside from varying the number of applied pulses, varying the width of each pulse from 20 microseconds to 100 microseconds produced a slight increase in the ablation size. Increasing the pulse width, however, also reduced the variance in ablation size (i.e., reduction in standard deviation). As the pulse width increased past 50-70 microseconds, the variance among the ablation sizes decreased substantially. This effect became more pronounced for longer spacing between the electrodes (e.g., greater than 3 cm). Thus, this information could also be used to increase the ablation size and also to more accurately predict the ablation size.


In procedures involving 3 or more electrodes, rather than applying the total number of electrodes sequentially for each pair, then moving on to the next pair, dividing up the total number of pulses to be delivered into smaller subsets and then applying each subset of pulses to each pair, and then repeating the sequence for the subsequent subsets while reversing the polarity for each sequence (i.e., E1(+)−E2(−), then E2(+)−E1(−) in the next sequence) produced an increase in the ablation size, especially when the total number of pulses for each pair was substantially higher than 100.


For a 3-electrode procedure and the total number of pulses=500, for example, the sequence of delivered pulses are as follows: 10 sequential IRE pulses per electrode pair for all pairs (e.g., 10 pulses for pair 1-2, then 10 pulses for pair 2-3 and then 10 pulses for pair 3-1). Then the same sequence is repeated 50 times for a total number of IRE pulses delivered of 500 per electrode pair with the electrode phase (polarity) being reversed after each sequence.



FIG. 9 illustrates ablation regions of different sizes that are displayed on the monitor 11 according to the number of pulses delivered. The original lesion or target area 300 has been increased to an enlarged target region 301 which adds a margin of error. The estimated ablation area 305 has been generated assuming that 100 pulses will be delivered with four electrodes positioned as shown (superimposed over the target region 301). As can be seen, the estimated ablation/treatment area 305 barely covers the original target area 300 and is clearly inadequate to cover the enlarged target region 301.


However, according to the present invention, the enlarged target region 301 can be adequately covered by an increased ablation area 325 which has been calculated based on 1000 pulses (and which has been superimposed over the target region 301). Since such a large treatment area 325 can damage too much of good tissue, after receiving identification of a target region, the treatment control module 54 can select/adjust the number of pulses or number of electrodes, or both so that the resulting estimated treatment area sufficiently covers the target region 301 while minimizing ablation of good tissue. One way to do so is to generate a plurality of estimated ablation regions based on a plurality of pulse count, and then selecting the minimum pulse count that completely covers the target region 301 while minimizing damage to good tissue.


Advantageously, the present invention allows treatment of larger ablation regions with fewer electrodes to thereby provide a safer and less expensive electrical ablation procedure for patients. The present invention also allows treatment of a larger ablation area without dividing up the area into multiple regions and repeating the procedure.


The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many modifications, variations, and alternatives may be made by ordinary skill in this art without departing from the scope of the invention. Those familiar with the art may recognize other equivalents to the specific embodiments described herein. Accordingly, the scope of the invention is not limited to the foregoing specification.

Claims
  • 1. A method of treating a target region of a tissue, the method comprising: disposing a plurality of electrodes near the target region; andactivating a generator to deliver electrical pulses to the target region via the plurality of electrodes, wherein: a total number of electrical pulses to be applied between the plurality of electrodes is divided into subsets of at least 10 electrical pulses,each subset is sequentially applied between the plurality of electrodes until all of the electrodes have been activated to define a pulse cycle, andthe pulse cycles are repeated until the total number of electrical pulses are applied,wherein a delay of between 250 milliseconds and 15 seconds is applied between each electrical pulse; andwherein a delay of between 5 seconds and 10 minutes is applied between each pulse subset.
  • 2. The method of claim 1, wherein the plurality of electrodes comprises two or more electrodes.
  • 3. The method of claim 1, wherein consecutive cycles of electrical pulses have opposite polarities.
  • 4. The method of claim 1, wherein the tissue comprises prostate tissue.
  • 5. The method of claim 1, wherein a delay of between 5 seconds to 20 minutes is applied between each pulse cycle.
  • 6. The method of claim 1, wherein each pulse cycle comprises 1 to 280 pulses to be delivered between the plurality of electrodes.
  • 7. The method of claim 1, wherein the pulse cycles are configured to allow for potential thermal buildup to dissipate or a reduction of potential gas buildup in the target region of the tissue surrounding the plurality of electrodes.
  • 8. The method of claim 1, wherein consecutive pulses within a subset alternate polarity.
  • 9. A method of electroporating a tissue, the method comprising: delivering a first subset of electrical pulses via a first pair of electrodes disposed within the tissue, wherein the first subset of electrical pulses is less than a total number of desired pulses to be applied by the first pair of electrodes;delivering a second subset of electrical pulses via a second pair of electrodes disposed within the tissue, wherein the second subset of electrical pulses is less than a total number of desired pulses to be applied by the second pair of electrodes, wherein the second pair of electrodes includes at least one different electrode from the first pair of electrodes; anddelivering additional subsets of electrical pulses via the first and second pairs of electrodes sequentially until the total number of desired pulses for each pair is delivered,wherein the tissue comprises prostate tissue.
  • 10. The method of claim 9, wherein the plurality of electrodes comprises three or more electrodes.
  • 11. The method of claim 9, wherein each subset of electrical pulses comprises at least 10 electrical pulses.
  • 12. The method of claim 11, wherein a delay of 250 milliseconds to 15 seconds is applied between each electrical pulse.
  • 13. The method of claim 12, wherein a delay of 5 seconds to 10 minutes is applied between each pulse subset of electrical pulses.
  • 14. The method of claim 9, wherein the electrical pulses are delivered in such a manner that the tissue is ablated by irreversible electroporation.
  • 15. The method of claim 9, wherein the electrical pulses are delivered in such a manner that thermal buildup in the tissue surrounding each electrode is substantially dissipated or gas buildup in the tissue surrounding each electrode is substantially dissipated.
  • 16. A method of irreversible electroporating a target tissue, the method comprising: electrically coupling a plurality of electrodes to a generator;disposing the plurality of electrodes near the target tissue; andactivating the generator to deliver electrical pulses to the target tissue via the plurality of electrodes, wherein:the electrical pulses are delivered in a cycled pulse sequence such that a total number of electrical pulses delivered between the plurality of electrodes is divided into subsets of electrical pulses, and the plurality of electrodes are activated in a sequential order to deliver the subsets of electrical pulses to define a pulse cycle, andthe pulse cycle is repeated until the total number of desired pulses are delivered,wherein the plurality of electrodes comprises two or more electrodes, each subset of electrical pulses comprises at least 10 electrical pulses, and a delay of between 5 seconds to 20 minutes is applied between each pulse cycle.
  • 17. The method of claim 16, wherein the tissue comprises prostate tissue.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a Continuation of U.S. Non-Provisional application Ser. No. 15/612,006, filed Jun. 2, 2017, which is a Continuation of U.S. Non-Provisional application Ser. No. 13/273,001, now U.S. Pat. No. 9,700,368, filed Oct. 13, 2011, which claims the benefit of U.S. Provisional Application No. 61/392,905, filed Oct. 13, 2010, all of which is incorporated by reference herein. This application is also related to PCT International Application Number PCT/US10/29243, filed Mar. 30, 2010 and entitled “System and Method for Estimating a Treatment Region for a Medical Treatment Device and for Interactively Planning a Treatment of a Patient” (hereinafter the “IRE Treatment Application”), which is incorporated herein by reference. This application is also related to PCT International Application Number PCT/US10/36734, filed May 28, 2010 and entitled “System and Method for Synchronizing Energy Delivery to the Cardiac Rhythm”, which is also incorporated herein by reference.

US Referenced Citations (1321)
Number Name Date Kind
1329496 Binkley Feb 1920 A
1351661 Kaufman Aug 1920 A
1376652 Steedman May 1921 A
1380272 Tomasulo May 1921 A
1430015 Icher Sep 1922 A
1437941 Hoover Dec 1922 A
1442697 Orthmann Jan 1923 A
1443360 Grace Jan 1923 A
1445198 Bornmann Feb 1923 A
1450391 Shaw Apr 1923 A
3437941 Leary Apr 1969 A
3634460 Nelson Jan 1972 A
3639545 Wilcox Feb 1972 A
3730238 Butler May 1973 A
3746004 Jankelson Jul 1973 A
3871359 Pacela Mar 1975 A
4016866 Lawton Apr 1977 A
4037341 Odle Jul 1977 A
4216860 Heimann Aug 1980 A
4224949 Scott Sep 1980 A
4267047 Henne May 1981 A
4278092 Borsanyi et al. Jul 1981 A
4299217 Sagae et al. Nov 1981 A
4304239 Perlin Dec 1981 A
4311148 Courtney Jan 1982 A
4336881 Babb et al. Jun 1982 A
4344436 Kubota Aug 1982 A
4392855 Oreopoulos Jul 1983 A
4406827 Carim Sep 1983 A
4416276 Newton et al. Nov 1983 A
4447235 Clarke May 1984 A
4469098 Davi Sep 1984 A
4489535 Veltman Dec 1984 A
4512765 Muto Apr 1985 A
4580572 Granek Apr 1986 A
4636199 Victor Jan 1987 A
4672969 Dew Jun 1987 A
4676258 Inokuchi Jun 1987 A
4676782 Yamamoto Jun 1987 A
4687471 Twardowski Aug 1987 A
4716896 Ackerman Jan 1988 A
4723549 Wholey Feb 1988 A
D294519 Hardy, Jr. Mar 1988 S
4756838 Veltman Jul 1988 A
4772269 Twardowski Sep 1988 A
4798585 Inoue Jan 1989 A
4813929 Semrad Mar 1989 A
4819637 Dormandy, Jr. Apr 1989 A
4822470 Chang Apr 1989 A
4836204 Landymore Jun 1989 A
4840172 Augustine Jun 1989 A
4863426 Ferragamo Sep 1989 A
4885003 Hillstead Dec 1989 A
4886496 Conoscenti Dec 1989 A
4886502 Poirier et al. Dec 1989 A
4889634 El-Rashidy Dec 1989 A
4903707 Knute Feb 1990 A
4919148 Muccio Apr 1990 A
4921484 Muccio Apr 1990 A
4920978 Colvin May 1990 A
4976709 Sand Dec 1990 A
4981477 Schon Jan 1991 A
4986810 Semrad Jan 1991 A
4987895 Heimlich Jan 1991 A
5031775 Kane Jul 1991 A
5053013 Ensminger Oct 1991 A
5071558 Itob Dec 1991 A
5122137 Lennox Jun 1992 A
5137517 Loney Aug 1992 A
5141499 Zappacosta Aug 1992 A
D329496 Wotton Sep 1992 S
5156597 Verreet Oct 1992 A
5186715 Phillips Feb 1993 A
5186800 Dower Feb 1993 A
5188592 Hakki Feb 1993 A
5190541 Abele Mar 1993 A
5192312 Orton Mar 1993 A
5209723 Twardowski et al. May 1993 A
5215530 Hogan Jun 1993 A
5222997 Montgomery Jun 1993 A
5224933 Bromander Jul 1993 A
5227730 King Jul 1993 A
5242415 Kantrowitz et al. Sep 1993 A
D343687 Houghton, II Jan 1994 S
5277201 Stern Jan 1994 A
5279564 Taylor Jan 1994 A
5281213 Milder Jan 1994 A
5290263 Wigness et al. Mar 1994 A
5308325 Quinn et al. May 1994 A
5308338 Helfrich May 1994 A
5318543 Ross Jun 1994 A
5334167 Cocanower Aug 1994 A
5348554 Imran Sep 1994 A
D351661 Fischer Oct 1994 S
5383917 Desai Jan 1995 A
5391158 Peters Feb 1995 A
5405320 Twardowski et al. Apr 1995 A
5417687 Nardella May 1995 A
5424752 Yamazaki Jun 1995 A
5439444 Andersen Aug 1995 A
5458597 Edwards Oct 1995 A
5462521 Brucker Oct 1995 A
5462644 Woodson Oct 1995 A
5484400 Edwards Jan 1996 A
5484401 Rodriguez Jan 1996 A
5536267 Edwards Jul 1996 A
5540737 Fenn Jul 1996 A
5542916 Hirsch Aug 1996 A
5546940 Panescu et al. Aug 1996 A
5562720 Stern et al. Oct 1996 A
D376652 Hunt Dec 1996 S
5582588 Sakurai et al. Dec 1996 A
5586982 Abela Dec 1996 A
5588424 Insler Dec 1996 A
5588960 Edwards et al. Dec 1996 A
5599294 Edwards Feb 1997 A
5599311 Raulerson Feb 1997 A
5616126 Malekmehr Apr 1997 A
5620479 Diederich Apr 1997 A
5630426 Eggers et al. May 1997 A
D380272 Partika Jun 1997 S
5643197 Brucker Jul 1997 A
5645855 Lorenz Jul 1997 A
5653684 Laptewicz Aug 1997 A
5672173 Gough Sep 1997 A
5672174 Gough Sep 1997 A
5681282 Eggers Oct 1997 A
5683384 Gough et al. Nov 1997 A
5687723 Avitall Nov 1997 A
5690620 Knott Nov 1997 A
5697905 D Ambrosio Dec 1997 A
5700252 Klingenstein Dec 1997 A
5707332 Weinberger Jan 1998 A
5718246 Vona Feb 1998 A
5728143 Gough Mar 1998 A
5735847 Gough et al. Apr 1998 A
5749914 Janssen May 1998 A
5752939 Makoto May 1998 A
5782827 Gough et al. Jul 1998 A
5800484 Gough et al. Sep 1998 A
5807272 Kun et al. Sep 1998 A
5807306 Shapland Sep 1998 A
5807395 Mulier Sep 1998 A
5810742 Pearlman Sep 1998 A
5810804 Gough Sep 1998 A
5830184 Basta Nov 1998 A
5836897 Sakurai et al. Nov 1998 A
5843182 Goldstein Dec 1998 A
5856081 Fahy Jan 1999 A
5863290 Gough et al. Jan 1999 A
5865787 Shapland et al. Feb 1999 A
5866756 Giros et al. Feb 1999 A
5868708 Hart Feb 1999 A
5873877 McGaffigan Feb 1999 A
5904648 Arndt et al. May 1999 A
5913855 Gough et al. Jun 1999 A
5919191 Lennox et al. Jul 1999 A
5921982 Lesh Jul 1999 A
5944710 Dev et al. Aug 1999 A
5947284 Foster Sep 1999 A
5951546 Lorentzen Sep 1999 A
5954745 Gertler Sep 1999 A
5957919 Laufer Sep 1999 A
5957963 Dobak, III Sep 1999 A
5968006 Hofmann Oct 1999 A
5983140 Smith Nov 1999 A
5984896 Boyd Nov 1999 A
5993466 Yoon Nov 1999 A
6004339 Wijay Dec 1999 A
6009647 Feingold Jan 2000 A
6009877 Edwards Jan 2000 A
6010452 Harcourt Jan 2000 A
6010616 Lewis Jan 2000 A
6012885 Taylor Jan 2000 A
6023638 Swanson Feb 2000 A
6029090 Herbst Feb 2000 A
6033402 Tu Mar 2000 A
6043066 Mangano Mar 2000 A
6050994 Sherman Apr 2000 A
6055456 Gerber Apr 2000 A
6059780 Gough May 2000 A
6066134 Eggers et al. May 2000 A
6068121 McGlinch May 2000 A
6071281 Burnside Jun 2000 A
6074374 Fulton Jun 2000 A
6074389 Levine et al. Jun 2000 A
6090016 Kuo Jul 2000 A
6090105 Zepeda et al. Jul 2000 A
D430015 Himbert Aug 2000 S
6096035 Sodhi Aug 2000 A
6106524 Eggers et al. Aug 2000 A
6110192 Ravenscroft et al. Aug 2000 A
6113593 Tu Sep 2000 A
6116330 Salyer Sep 2000 A
6120493 Hofmann Sep 2000 A
6123701 Nezhat Sep 2000 A
6132397 Davis et al. Oct 2000 A
6134460 Chance Oct 2000 A
6135999 Fanton Oct 2000 A
6139544 Mikus Oct 2000 A
6139545 Utley et al. Oct 2000 A
6142992 Cheng Nov 2000 A
6150148 Nanda Nov 2000 A
6152923 Ryan Nov 2000 A
6178354 Gibson Jan 2001 B1
D437941 Frattini Feb 2001 S
6193715 Wrublewski et al. Feb 2001 B1
6198970 Freed Mar 2001 B1
6200314 Sherman Mar 2001 B1
D442697 Hajianpour May 2001 S
6233490 Kasevich May 2001 B1
6235023 Lee May 2001 B1
D443360 Haberland Jun 2001 S
6241725 Cosman Jun 2001 B1
D445198 Frattini Jul 2001 S
6258100 Alferness Jul 2001 B1
6258249 Simpson Jul 2001 B1
6277114 Bullivant et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283988 Laufer Sep 2001 B1
6283989 Laufer Sep 2001 B1
6284140 Sommermeyer Sep 2001 B1
6287293 Jones et al. Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6296636 Cheng Oct 2001 B1
6298726 Adachi Oct 2001 B1
6299633 Laufer Oct 2001 B1
D450391 Hunt Nov 2001 S
6312428 Eggers Nov 2001 B1
6327505 Medhkour Dec 2001 B1
6328689 Gonzalez et al. Dec 2001 B1
6328735 Curley Dec 2001 B1
6330478 Lee Dec 2001 B1
6375634 Carroll Apr 2002 B1
6398779 Buysse Jun 2002 B1
6403347 Bills Jun 2002 B1
6405732 Edwards Jun 2002 B1
6411852 Danek Jun 2002 B1
6419674 Bowser Jul 2002 B1
6428802 Atala Aug 2002 B1
6437551 Krulevitch Aug 2002 B1
6443952 Mulier et al. Sep 2002 B1
6463331 Edwards Oct 2002 B1
6478793 Cosman Nov 2002 B1
6482221 Hebert et al. Nov 2002 B1
6485487 Sherman Nov 2002 B1
6488673 Laufer Dec 2002 B1
6488678 Sherman Dec 2002 B2
6488680 Francischelli et al. Dec 2002 B1
6491706 Alferness Dec 2002 B1
6493569 Foo Dec 2002 B2
6493589 Medhkour Dec 2002 B1
6497704 Ein-Gal Dec 2002 B2
6503248 Levine Jan 2003 B1
6506189 Rittman, III et al. Jan 2003 B1
6514248 Eggers et al. Feb 2003 B1
6520183 Amar Feb 2003 B2
D471640 McMichael Mar 2003 S
D471641 McMichael Mar 2003 S
6533784 Truckai Mar 2003 B2
6537976 Gupta Mar 2003 B1
6540695 Burbank Apr 2003 B1
6558378 Sherman May 2003 B2
6569162 He May 2003 B2
6575967 Leveen Jun 2003 B1
6575969 Rittman, III Jun 2003 B1
6589161 Corcoran Jul 2003 B2
6589174 Chopra et al. Jul 2003 B1
6592594 Rimbaugh Jul 2003 B2
6610054 Edwards Aug 2003 B1
6616657 Simpson Sep 2003 B2
D480816 McMichael Oct 2003 S
6634363 Danek et al. Oct 2003 B1
6638253 Breznock Oct 2003 B2
6638275 McGaffigan Oct 2003 B1
6666858 Lafontaine Dec 2003 B2
6673070 Edwards et al. Jan 2004 B2
6678558 Dimmer et al. Jan 2004 B1
6682501 Nelson Jan 2004 B1
6689096 Loubens et al. Feb 2004 B1
6689127 Gough et al. Feb 2004 B1
6694170 Mikus Feb 2004 B1
6694964 Wu Feb 2004 B2
6694979 Deem Feb 2004 B2
6694984 Habib Feb 2004 B2
6695861 Rosenberg Feb 2004 B1
6712811 Underwood Mar 2004 B2
D489973 Root May 2004 S
6733516 Simons May 2004 B2
6753171 Karube Jun 2004 B2
6761716 Kadhiresan Jul 2004 B2
6770070 Balbierz Aug 2004 B1
D495807 Agbodoe Sep 2004 S
6812204 McHale Nov 2004 B1
6837886 Collins Jan 2005 B2
6847848 Sterzer Jan 2005 B2
6860847 Alferness Mar 2005 B2
6869430 Balbierz Mar 2005 B2
6881213 Ryan Apr 2005 B2
6895267 Panescu May 2005 B2
6905480 McGuckin, Jr. Jun 2005 B2
6926713 Rioux Aug 2005 B2
6941950 Wilson Sep 2005 B2
6942681 Johnson Sep 2005 B2
6958062 Gough Oct 2005 B1
6960189 Bates Nov 2005 B2
6972013 Zhang Dec 2005 B1
6989010 Francischelli Jan 2006 B2
6994689 Zadno-Azizi Feb 2006 B1
7008421 Daniel Mar 2006 B2
7011094 Rapacki Mar 2006 B2
7012061 Reiss Mar 2006 B1
7027869 Danek Apr 2006 B2
7036510 Zgoda May 2006 B2
7054665 Turner May 2006 B2
7054685 Dimmer May 2006 B2
7087040 McGuckin, Jr. Aug 2006 B2
7097612 Bertolero Aug 2006 B2
7100616 Springmeyer Sep 2006 B2
7113821 Sun Sep 2006 B1
7162303 Levin Jan 2007 B2
7169107 Jersey-Willuhn Jan 2007 B2
7232437 Berman Jun 2007 B2
7250048 Francischelli Jul 2007 B2
D549332 Matsumoto Aug 2007 S
7257450 Auth Aug 2007 B2
7264002 Danek Sep 2007 B2
7273055 Danek Sep 2007 B2
7291146 Steinke Nov 2007 B2
7331940 Sommerich Feb 2008 B2
7331949 Marisi Feb 2008 B2
7341558 De La Torre Mar 2008 B2
7344533 Pearson Mar 2008 B2
D565743 Phillips Apr 2008 S
D571478 Horacek Jun 2008 S
7387626 Edwards Jun 2008 B2
7399747 Clair Jul 2008 B1
D575399 Matsumoto Aug 2008 S
D575402 Sandor Aug 2008 S
7412977 Fields Aug 2008 B2
7419487 Johnson Sep 2008 B2
7434578 Dillard Oct 2008 B2
7437194 Skwarek Oct 2008 B2
7449019 Uchida Nov 2008 B2
7451765 Adler Nov 2008 B2
7455675 Schur Nov 2008 B2
7476203 Devore Jan 2009 B2
7488292 Adachi Feb 2009 B2
7520877 Lee, Jr. Apr 2009 B2
7533671 Gonzalez May 2009 B2
D595422 Mustapha Jun 2009 S
7544301 Shah Jun 2009 B2
7549984 Mathis Jun 2009 B2
7553309 Buysse Jun 2009 B2
7565208 Harris Jul 2009 B2
7571729 Saadat Aug 2009 B2
7617005 Demarais Nov 2009 B2
7620451 Demarais Nov 2009 B2
7620507 Richardson Nov 2009 B2
7632291 Stephens Dec 2009 B2
7647115 Levin Jan 2010 B2
7653438 Deem Jan 2010 B2
7655004 Long Feb 2010 B2
7670333 Schatzberger Mar 2010 B2
7674249 Ivorra Mar 2010 B2
7680543 Azure Mar 2010 B2
D613418 Ryan Apr 2010 S
7699842 Buysse Apr 2010 B2
7706865 Snell Apr 2010 B1
7717948 Demarais May 2010 B2
7718409 Rubinsky May 2010 B2
7722606 Azure May 2010 B2
7742795 Stone Jun 2010 B2
7763018 Decarlo Jul 2010 B2
7765010 Chornenky Jul 2010 B2
7771401 Hekmat Aug 2010 B2
7776035 Rick Aug 2010 B2
7815571 Deckman Oct 2010 B2
7815662 Spivey Oct 2010 B2
7824870 Kovalcheck Nov 2010 B2
RE42016 Chornenky et al. Dec 2010 E
7846108 Turovskiy Dec 2010 B2
7853333 Demarais Dec 2010 B2
D630321 Hamilton, Jr. Jan 2011 S
D631154 Hamilton, Jr. Jan 2011 S
7874986 Deckman Jan 2011 B2
7875025 Cockburn Jan 2011 B2
7879031 Peterson Feb 2011 B2
RE42277 Jaafar et al. Apr 2011 E
7918852 Tullis Apr 2011 B2
7937143 Demarais May 2011 B2
7938824 Chornenky May 2011 B2
7951582 Gazit May 2011 B2
7955827 Rubinsky Jun 2011 B2
RE42835 Chornenky Oct 2011 E
D647628 Helfteren Oct 2011 S
8029504 Long Oct 2011 B2
8037591 Spivey Oct 2011 B2
8048067 Davalos Nov 2011 B2
8052604 Lau Nov 2011 B2
8057391 Lau Nov 2011 B2
8062290 Buysse Nov 2011 B2
RE43009 Chornenky Dec 2011 E
8070759 Stefanchik Dec 2011 B2
8075572 Stefanchik Dec 2011 B2
8088072 Munrow Jan 2012 B2
8100922 Griffith Jan 2012 B2
8109926 Azure Feb 2012 B2
8114070 Rubinsky Feb 2012 B2
8114072 Long Feb 2012 B2
8114119 Spivey Feb 2012 B2
8131371 Demarals Mar 2012 B2
8131372 Levin Mar 2012 B2
8145316 Deem Mar 2012 B2
8145317 Demarais Mar 2012 B2
8150518 Levin Apr 2012 B2
8150519 Demarais Apr 2012 B2
8150520 Demarais Apr 2012 B2
8154288 Deimling Apr 2012 B2
8157834 Conlon Apr 2012 B2
8162918 Ivorra Apr 2012 B2
8172772 Zwolinski May 2012 B2
8174267 Brannan May 2012 B2
8175711 Demarais May 2012 B2
8180433 Brannan May 2012 B2
8181995 Decarlo May 2012 B2
8182477 Orszulak May 2012 B2
8187269 Shadduck May 2012 B2
8187270 Auth May 2012 B2
8206300 Deckman Jun 2012 B2
8211097 Leyh Jul 2012 B2
8211099 Buysse Jul 2012 B2
8211125 Spivey Jul 2012 B2
8216161 Darlington Jul 2012 B2
8221411 Francischelli Jul 2012 B2
8231603 Hobbs Jul 2012 B2
8240468 Wilkinson Aug 2012 B2
8241204 Spivey Aug 2012 B2
8242782 Brannan Aug 2012 B2
8246615 Behnke Aug 2012 B2
8248075 Brannan Aug 2012 B2
8251986 Chornenky Aug 2012 B2
8252057 Fox Aug 2012 B2
8262563 Bakos Sep 2012 B2
8262577 Munrow Sep 2012 B2
8262655 Ghabrial Sep 2012 B2
8262680 Swain Sep 2012 B2
8267884 Hicks Sep 2012 B1
8267927 Dalal Sep 2012 B2
8267936 Hushka Sep 2012 B2
8277379 Lau Oct 2012 B2
8282631 Davalos Oct 2012 B2
8287527 Brannan Oct 2012 B2
8292880 Prakash Oct 2012 B2
8298222 Rubinsky Oct 2012 B2
8303516 Schmitz Nov 2012 B2
8317806 Coe Nov 2012 B2
8337394 Vakharia Dec 2012 B2
8343144 Kleyman Jan 2013 B2
8346370 Haley Jan 2013 B2
8347891 Demarais Jan 2013 B2
8348921 Ivorra Jan 2013 B2
8348938 Blomgren Jan 2013 B2
8353487 Trusty Jan 2013 B2
8353902 Prakash Jan 2013 B2
8361006 Kraemer Jan 2013 B2
8361066 Long Jan 2013 B2
8361112 Carroll, II Jan 2013 B2
8366712 Bleich Feb 2013 B2
8377057 Rick Feb 2013 B2
8380283 Krieg Feb 2013 B2
D677798 Hart Mar 2013 S
8394092 Brannan Mar 2013 B2
8394102 Garabedian Mar 2013 B2
8398626 Buysse Mar 2013 B2
8398641 Wallace Mar 2013 B2
8403924 Behnke Mar 2013 B2
8403926 Nobis Mar 2013 B2
8409200 Holcomb Apr 2013 B2
8409206 Wallace Apr 2013 B2
8417328 Sarfaty Apr 2013 B2
8425455 Nentwick Apr 2013 B2
8425505 Long Apr 2013 B2
8433423 Demarais Apr 2013 B2
8437845 Sarfaty May 2013 B2
8439907 Auth May 2013 B2
8444640 Demarais May 2013 B2
8449538 Long May 2013 B2
8454594 Demarais Jun 2013 B2
8465464 Travis Jun 2013 B2
8465484 Davalos Jun 2013 B2
8469716 Fedotov Jun 2013 B2
8473067 Hastings Jun 2013 B2
8480657 Bakos Jul 2013 B2
8480665 Decarlo Jul 2013 B2
8480666 Buysse Jul 2013 B2
8480689 Spivey Jul 2013 B2
8489192 Hlavka Jul 2013 B1
8496574 Trusty Jul 2013 B2
8506485 Deckman Aug 2013 B2
8506564 Long Aug 2013 B2
8511317 Thapliyal Aug 2013 B2
8512329 Paulus Aug 2013 B2
8512330 Epstein Aug 2013 B2
8518031 Boyden Aug 2013 B2
8529563 Long Sep 2013 B2
8542019 Brannan Sep 2013 B2
8546979 Heeren Oct 2013 B2
8548600 Deem Oct 2013 B2
8551069 Demarais Oct 2013 B2
8551088 Falkenstein Oct 2013 B2
8551097 Schmitz Oct 2013 B2
8562588 Hobbs Oct 2013 B2
8562598 Falkenstein Oct 2013 B2
8562599 Leyh Oct 2013 B2
8562602 Azure Oct 2013 B2
8568401 Brannan Oct 2013 B2
8568402 Buysse Oct 2013 B2
8568404 Brannan Oct 2013 B2
8568410 Vakharia Oct 2013 B2
8568411 Falkenstein Oct 2013 B2
8579894 Falkenstein Nov 2013 B2
8579897 Vakharia Nov 2013 B2
8579902 Bleich Nov 2013 B2
8585704 Schmitz Nov 2013 B2
8603087 Rubinsky Dec 2013 B2
8608652 Voegele Dec 2013 B2
8608739 Sartor Dec 2013 B2
8613745 Bleich Dec 2013 B2
8617163 Bleich Dec 2013 B2
8620423 Demarais Dec 2013 B2
8626300 Demarais Jan 2014 B2
8632534 Pearson Jan 2014 B2
8634929 Chornenky Jan 2014 B2
8647338 Chornenky Feb 2014 B2
8647346 Bleich Feb 2014 B2
8652130 Kreindel Feb 2014 B2
8652138 Bleich Feb 2014 B2
8652150 Swain Feb 2014 B2
8663210 Tomasello Mar 2014 B2
8663228 Schmitz Mar 2014 B2
8668688 Rusin Mar 2014 B2
8672937 Decarlo Mar 2014 B2
8679003 Spivey Mar 2014 B2
8684998 Demarais Apr 2014 B2
8702697 Curley Apr 2014 B2
8706258 Nabors, Sr. Apr 2014 B2
8712500 Schmidt Apr 2014 B2
8715276 Thompson May 2014 B2
8721637 Zarins May 2014 B2
8725249 Bar-Yoseph May 2014 B2
8728137 Zarins May 2014 B2
8728138 Zarins May 2014 B2
8728139 Azure May 2014 B2
8731672 Hlavka May 2014 B2
8740895 Mayse Jun 2014 B2
8740896 Zarins Jun 2014 B2
8753335 Moshe Jun 2014 B2
8768470 Deem Jul 2014 B2
8771252 Gelfand Jul 2014 B2
8771260 Conlon Jul 2014 B2
8774913 Demarais Jul 2014 B2
8774922 Zarins Jul 2014 B2
8777943 Mayse Jul 2014 B2
8784463 Zarins Jul 2014 B2
8797039 Brannan Aug 2014 B2
8801626 Sun Aug 2014 B2
8805545 Zarins Aug 2014 B2
8808280 Mayse Aug 2014 B2
8814860 Davalos Aug 2014 B2
8818514 Zarins Aug 2014 B2
8821489 Mayse Sep 2014 B2
8828031 Fox Sep 2014 B2
8835166 Phillips Sep 2014 B2
8845559 Darlington Sep 2014 B2
8845629 Demarais Sep 2014 B2
8845635 Daniel Sep 2014 B2
8845639 Wallace Sep 2014 B2
8852163 Deem Oct 2014 B2
8858550 Busch-Madsen Oct 2014 B2
8865076 Sarfaty Oct 2014 B2
8880185 Hastings Nov 2014 B2
8880186 Levin Nov 2014 B2
8880195 Azure Nov 2014 B2
8882759 Manley Nov 2014 B2
8888792 Harris Nov 2014 B2
8894641 Brannan Nov 2014 B2
8903488 Callas Dec 2014 B2
8906006 Chornenky Dec 2014 B2
8906011 Gelbart Dec 2014 B2
8906035 Zwolinski Dec 2014 B2
8911439 Mayse Dec 2014 B2
8915910 Falkenstein Dec 2014 B2
8915911 Azure Dec 2014 B2
8920411 Gelbart Dec 2014 B2
8923970 Bar-Yoseph Dec 2014 B2
8926606 Davalos Jan 2015 B2
8932287 Gelbart Jan 2015 B2
8932289 Mayse Jan 2015 B2
8934978 Deem Jan 2015 B2
8939897 Nobis Jan 2015 B2
8939970 Stone Jan 2015 B2
8945121 Curley Feb 2015 B2
8948865 Zarins Feb 2015 B2
8956350 Buysse Feb 2015 B2
8958871 Demarais Feb 2015 B2
8958888 Chornenky Feb 2015 B2
8961507 Mayse Feb 2015 B2
8961508 Mayse Feb 2015 B2
8968542 Davalos Mar 2015 B2
8974451 Smith Mar 2015 B2
8983595 Levin Mar 2015 B2
8986294 Demarais Mar 2015 B2
8992517 Davalos Mar 2015 B2
9005189 Davalos Apr 2015 B2
9005195 Mayse Apr 2015 B2
9005198 Long Apr 2015 B2
9011431 Long Apr 2015 B2
9017323 Miller Apr 2015 B2
9017324 Mayse Apr 2015 B2
9023034 Jenson May 2015 B2
9023037 Zarins May 2015 B2
9028483 Long May 2015 B2
9028485 Edmunds May 2015 B2
9039702 Miller May 2015 B2
9049987 Conlon Jun 2015 B2
9050449 Darlington Jun 2015 B2
9060761 Hastings Jun 2015 B2
9072518 Swanson Jul 2015 B2
9072527 Deem Jul 2015 B2
9078665 Moss Jul 2015 B2
9084609 Smith Jul 2015 B2
9089350 Willard Jul 2015 B2
9101386 Wallace Aug 2015 B2
9108040 Zarins Aug 2015 B2
9113888 Orszulak Aug 2015 B2
9119633 Gelbart Sep 2015 B2
9119634 Gelbart Sep 2015 B2
9125643 Hlavka Sep 2015 B2
9125661 Deem Sep 2015 B2
9125666 Steinke Sep 2015 B2
9125667 Stone Sep 2015 B2
9131978 Zarins Sep 2015 B2
9138281 Zarins Sep 2015 B2
9138287 Curley Sep 2015 B2
9138288 Curley Sep 2015 B2
9149328 Dimmer Oct 2015 B2
9149331 Deem Oct 2015 B2
9155589 Jenson Oct 2015 B2
9173704 Hobbs Nov 2015 B2
9186198 Demarais Nov 2015 B2
9186209 Weber Nov 2015 B2
9186213 Deem Nov 2015 B2
9192435 Jenson Nov 2015 B2
9192715 Gelfand Nov 2015 B2
9192790 Hastings Nov 2015 B2
9198733 Neal, II Dec 2015 B2
9220526 Conlon Dec 2015 B2
9220558 Willard Dec 2015 B2
9220561 Crow Dec 2015 B2
9226772 Fox Jan 2016 B2
9226790 Zemel Jan 2016 B2
9233241 Long Jan 2016 B2
9247952 Bleich Feb 2016 B2
9248318 Darlington Feb 2016 B2
9254169 Long Feb 2016 B2
9254172 Behnke, II Feb 2016 B2
9265557 Sherman Feb 2016 B2
9265558 Zarins Feb 2016 B2
9276367 Brannan Mar 2016 B2
9277955 Herscher Mar 2016 B2
9277969 Brannan Mar 2016 B2
9283051 Garcia Mar 2016 B2
9289255 Deem Mar 2016 B2
9295516 Pearson Mar 2016 B2
9307935 Pluta Apr 2016 B2
9308039 Azure Apr 2016 B2
9308043 Zarins Apr 2016 B2
9308044 Zarins Apr 2016 B2
9314620 Long Apr 2016 B2
9314630 Levin Apr 2016 B2
9320561 Zarins Apr 2016 B2
9320563 Brustad Apr 2016 B2
9326751 Hastings May 2016 B2
9326817 Zarins May 2016 B2
9327100 Perry May 2016 B2
9327122 Zarins May 2016 B2
9339618 Deem May 2016 B2
9351790 Zemel May 2016 B2
9414881 Callas Aug 2016 B2
9598691 Davalos Mar 2017 B2
9700368 Callas Jul 2017 B2
9764145 Callas Sep 2017 B2
9867652 Sano Jan 2018 B2
9943599 Gehl Apr 2018 B2
10010666 Rubinsky Jul 2018 B2
10117701 Davalos Nov 2018 B2
10117707 Garcia Nov 2018 B2
10143512 Rubinsky Dec 2018 B2
10154874 Davalos Dec 2018 B2
10238447 Neal, II Mar 2019 B2
10245098 Davalos Apr 2019 B2
10245105 Davalos Apr 2019 B2
10272178 Davalos Apr 2019 B2
10286108 Davalos May 2019 B2
10292755 Arena May 2019 B2
10342600 Callas Jul 2019 B2
10448989 Arena Oct 2019 B2
10470822 Garcia Nov 2019 B2
10471254 Sano Nov 2019 B2
10537379 Sano Jan 2020 B2
10668208 Rubinsky Jun 2020 B2
10694972 Davalos Jun 2020 B2
10702326 Neal, II Jul 2020 B2
10828085 Davalos Nov 2020 B2
10828086 Davalos Nov 2020 B2
10905492 Neal, II Feb 2021 B2
10959772 Davalos Mar 2021 B2
11254926 Neal, II Feb 2022 B2
11272979 Garcia Mar 2022 B2
11311329 Davalos Apr 2022 B2
11382681 Arena Jul 2022 B2
11406820 Sano Aug 2022 B2
11453873 Davalos Sep 2022 B2
11607271 Garcia Mar 2023 B2
11607537 Latouche Mar 2023 B2
11638603 Sano May 2023 B2
11655466 Neal, II May 2023 B2
11737810 Davalos Aug 2023 B2
20010014819 Ingle Aug 2001 A1
20010039393 Mori Nov 2001 A1
20010043706 Masuda Nov 2001 A1
20010046706 Rubinsky Nov 2001 A1
20010047167 Heggeness Nov 2001 A1
20010051366 Rubinsky Dec 2001 A1
20020002393 Mitchell Jan 2002 A1
20020022864 Mahvi Feb 2002 A1
20020040204 Dev Apr 2002 A1
20020049370 Laufer Apr 2002 A1
20020052601 Goldberg May 2002 A1
20020065541 Fredricks May 2002 A1
20020072742 Schaefer Jun 2002 A1
20020077314 Falk Jun 2002 A1
20020077627 Johnson Jun 2002 A1
20020082543 Park Jun 2002 A1
20020091362 Maginot Jul 2002 A1
20020095197 Lardo Jul 2002 A1
20020104318 Jaafar Aug 2002 A1
20020111615 Cosman Aug 2002 A1
20020112729 Devore Aug 2002 A1
20020115208 Mitchell Aug 2002 A1
20020119437 Grooms Aug 2002 A1
20020120261 Morris Aug 2002 A1
20020133324 Weaver Sep 2002 A1
20020137121 Rubinsky Sep 2002 A1
20020138075 Edwards Sep 2002 A1
20020143365 Herbst Oct 2002 A1
20020147462 Mair Oct 2002 A1
20020156472 Lee Oct 2002 A1
20020161361 Sherman Oct 2002 A1
20020183684 Dev Dec 2002 A1
20020183735 Edwards Dec 2002 A1
20020183740 Edwards Dec 2002 A1
20020188242 Wu Dec 2002 A1
20020193784 McHale Dec 2002 A1
20030009165 Edwards Jan 2003 A1
20030014047 Woloszko Jan 2003 A1
20030016168 Jandrell Jan 2003 A1
20030055220 Legrain Mar 2003 A1
20030059945 Dzekunov Mar 2003 A1
20030074039 Puskas Apr 2003 A1
20030078490 Damasco Apr 2003 A1
20030088199 Kawaji May 2003 A1
20030096407 Atala May 2003 A1
20030105454 Cucin Jun 2003 A1
20030109871 Johnson Jun 2003 A1
20030127090 Gifford Jul 2003 A1
20030135242 Mongeon Jul 2003 A1
20030149451 Chomenky Aug 2003 A1
20030153960 Chornenky Aug 2003 A1
20030154988 Devore Aug 2003 A1
20030159700 Laufer Aug 2003 A1
20030164168 Shaw Sep 2003 A1
20030166181 Rubinsky Sep 2003 A1
20030194808 Rubinsky Oct 2003 A1
20030195385 Devore Oct 2003 A1
20030195406 Jenkins Oct 2003 A1
20030199050 Mangano Oct 2003 A1
20030208236 Heil Nov 2003 A1
20030212394 Pearson Nov 2003 A1
20030212412 Dillard Nov 2003 A1
20030228344 Fields Dec 2003 A1
20030233091 Whayne Dec 2003 A1
20040009459 Anderson Jan 2004 A1
20040055606 Hendricksen Mar 2004 A1
20040059328 Daniel Mar 2004 A1
20040068228 Cunningham Apr 2004 A1
20040116935 Lechot Jun 2004 A1
20040116965 Falkenberg Jun 2004 A1
20040133194 Eum Jul 2004 A1
20040138715 Van Groeningen Jul 2004 A1
20040167458 Draghia-Akli Aug 2004 A1
20040172136 Ralph Sep 2004 A1
20040176855 Badylak Sep 2004 A1
20040187875 He Sep 2004 A1
20040193042 Scampini Sep 2004 A1
20040193097 Hofmann Sep 2004 A1
20040199159 Lee Oct 2004 A1
20040200484 Springmeyer Oct 2004 A1
20040206349 Alferness Oct 2004 A1
20040210248 Gordon Oct 2004 A1
20040236376 Miklavcic Nov 2004 A1
20040237340 Rembrandt Dec 2004 A1
20040267256 Garabedian Dec 2004 A1
20040267340 Cioanta Dec 2004 A1
20050004507 Schroeppel Jan 2005 A1
20050010209 Lee Jan 2005 A1
20050010259 Gerber Jan 2005 A1
20050013726 Hill Jan 2005 A1
20050013870 Freyman Jan 2005 A1
20050019830 Penner Jan 2005 A1
20050020965 Rioux Jan 2005 A1
20050033276 Adachi Feb 2005 A1
20050048651 Ryttsen Mar 2005 A1
20050054978 Segal Mar 2005 A1
20050061322 Freitag Mar 2005 A1
20050063974 Reinhard Mar 2005 A1
20050066974 Fields Mar 2005 A1
20050096537 Parel May 2005 A1
20050096709 Skwarek May 2005 A1
20050107781 Ostrovsky May 2005 A1
20050112141 Terman May 2005 A1
20050135393 Benco Jun 2005 A1
20050143817 Hunter Jun 2005 A1
20050171522 Christopherson Aug 2005 A1
20050171571 Goodin Aug 2005 A1
20050197619 Rule Sep 2005 A1
20050203489 Saadat Sep 2005 A1
20050216047 Kumoyama Sep 2005 A1
20050228373 Kelly Oct 2005 A1
20050228459 Levin Oct 2005 A1
20050228460 Levin Oct 2005 A1
20050234445 Conquergood Oct 2005 A1
20050234523 Levin Oct 2005 A1
20050261707 Schatzberger Nov 2005 A1
20050267407 Goldman Dec 2005 A1
20050282284 Rubinsky Dec 2005 A1
20050283149 Thorne Dec 2005 A1
20050288684 Aronson Dec 2005 A1
20050288702 McGurk Dec 2005 A1
20060004356 Bilski Jan 2006 A1
20060004400 McGurk Jan 2006 A1
20060009748 Mathis Jan 2006 A1
20060020347 Barrett Jan 2006 A1
20060024359 Walker Feb 2006 A1
20060025821 Gelfand Feb 2006 A1
20060030810 Mandrusov Feb 2006 A1
20060074413 Behzadian Apr 2006 A1
20060079838 Walker Apr 2006 A1
20060079845 Howard Apr 2006 A1
20060085054 Zikorus Apr 2006 A1
20060089635 Young Apr 2006 A1
20060106379 O'Brien May 2006 A1
20060127703 Takekuma Jun 2006 A1
20060142801 Demarais Jun 2006 A1
20060149123 Vidlund Jul 2006 A1
20060173490 Lafontaine Aug 2006 A1
20060182684 Beliveau Aug 2006 A1
20060184163 Breen Aug 2006 A1
20060195146 Tracey Aug 2006 A1
20060206150 Demarais Sep 2006 A1
20060212032 Daniel Sep 2006 A1
20060212076 Demarais Sep 2006 A1
20060217702 Young Sep 2006 A1
20060217704 Cockburn Sep 2006 A1
20060224188 Libbus Oct 2006 A1
20060224192 Dimmer Oct 2006 A1
20060234752 Mese Oct 2006 A1
20060235474 Demarais Oct 2006 A1
20060241366 Falwell Oct 2006 A1
20060247619 Kaplan Nov 2006 A1
20060264807 Westersten Nov 2006 A1
20060269531 Beebe Nov 2006 A1
20060271111 Demarais Nov 2006 A1
20060276710 Krishnan Dec 2006 A1
20060278241 Ruano Dec 2006 A1
20060283462 Fields Dec 2006 A1
20060293713 Rubinsky Dec 2006 A1
20060293725 Rubinsky Dec 2006 A1
20060293730 Rubinsky Dec 2006 A1
20060293731 Rubinsky Dec 2006 A1
20060293734 Scott Dec 2006 A1
20070016125 Wong Jan 2007 A1
20070016183 Lee Jan 2007 A1
20070016185 Tullis Jan 2007 A1
20070021803 Deem Jan 2007 A1
20070025919 Deem Feb 2007 A1
20070043345 Davalos Feb 2007 A1
20070055142 Webler Mar 2007 A1
20070055225 Dodd, III Mar 2007 A1
20070060989 Deem Mar 2007 A1
20070066957 Demarais Mar 2007 A1
20070066971 Podhajsky Mar 2007 A1
20070078391 Wortley Apr 2007 A1
20070078453 Johnson Apr 2007 A1
20070083239 Demarais Apr 2007 A1
20070088347 Young Apr 2007 A1
20070093789 Smith Apr 2007 A1
20070096048 Clerc May 2007 A1
20070129711 Altshuler Jun 2007 A1
20070129720 Demarais Jun 2007 A1
20070129760 Demarais Jun 2007 A1
20070137567 Shimizu Jun 2007 A1
20070151848 Novak Jul 2007 A1
20070153135 Han Jul 2007 A1
20070156129 Kovalcheck Jul 2007 A1
20070156135 Rubinsky Jul 2007 A1
20070156136 Godara Jul 2007 A1
20070173899 Levin Jul 2007 A1
20070179380 Grossman Aug 2007 A1
20070191589 Hirota Aug 2007 A1
20070191889 Lang Aug 2007 A1
20070197895 Nycz Aug 2007 A1
20070203486 Young Aug 2007 A1
20070203549 Demarais Aug 2007 A1
20070230757 Trachtenberg Oct 2007 A1
20070239099 Goldfarb Oct 2007 A1
20070244521 Bornzin Oct 2007 A1
20070249939 Gerbi Oct 2007 A1
20070282407 Demarais Dec 2007 A1
20070287950 Kjeken Dec 2007 A1
20070295336 Nelson Dec 2007 A1
20070295337 Nelson Dec 2007 A1
20080015571 Rubinsky Jan 2008 A1
20080015628 Dubrul Jan 2008 A1
20080021371 Rubinsky Jan 2008 A1
20080027314 Miyazaki Jan 2008 A1
20080027343 Fields Jan 2008 A1
20080033340 Heller Feb 2008 A1
20080033417 Nields Feb 2008 A1
20080045880 Kjeken Feb 2008 A1
20080065062 Leung Mar 2008 A1
20080071262 Azure Mar 2008 A1
20080071264 Azure Mar 2008 A1
20080071265 Azure Mar 2008 A1
20080082145 Skwarek Apr 2008 A1
20080086115 Stoklund Apr 2008 A1
20080091135 Draghia-Akli Apr 2008 A1
20080097139 Clerc Apr 2008 A1
20080097422 Edwards Apr 2008 A1
20080103529 Schoenbach May 2008 A1
20080121375 Richason May 2008 A1
20080125772 Stone May 2008 A1
20080125775 Morris May 2008 A1
20080132826 Shadduck Jun 2008 A1
20080132884 Rubinsky Jun 2008 A1
20080132885 Rubinsky Jun 2008 A1
20080140064 Vegesna Jun 2008 A1
20080146931 Zhang Jun 2008 A1
20080146934 Czygan Jun 2008 A1
20080147056 Van Der Weide Jun 2008 A1
20080154259 Gough Jun 2008 A1
20080167649 Edwards Jul 2008 A1
20080171985 Karakoca Jul 2008 A1
20080183256 Keacher Jul 2008 A1
20080190434 Tjong Joe Wai Aug 2008 A1
20080200911 Long Aug 2008 A1
20080200912 Long Aug 2008 A1
20080208052 Lepivert Aug 2008 A1
20080210243 Clayton Sep 2008 A1
20080213331 Gelfand Sep 2008 A1
20080214986 Ivorra Sep 2008 A1
20080224188 Han Sep 2008 A1
20080234708 Houser Sep 2008 A1
20080236593 Nelson Oct 2008 A1
20080249503 Fields Oct 2008 A1
20080255553 Young Oct 2008 A1
20080262489 Steinke Oct 2008 A1
20080269586 Rubinsky Oct 2008 A1
20080269838 Brighton Oct 2008 A1
20080275465 Paul Nov 2008 A1
20080279995 Schultheiss Nov 2008 A1
20080281319 Paul Nov 2008 A1
20080283065 Chang Nov 2008 A1
20080288038 Paul Nov 2008 A1
20080294155 Cronin Nov 2008 A1
20080294358 Richardson Nov 2008 A1
20080306427 Bailey Dec 2008 A1
20080312599 Rosenberg Dec 2008 A1
20080319511 Pless Dec 2008 A1
20090018206 Barkan Jan 2009 A1
20090018565 To Jan 2009 A1
20090018566 Escudero Jan 2009 A1
20090018567 Escudero Jan 2009 A1
20090024075 Schroeppel Jan 2009 A1
20090024085 To Jan 2009 A1
20090029407 Gazit Jan 2009 A1
20090030336 Woo Jan 2009 A1
20090036773 Lau Feb 2009 A1
20090038752 Weng Feb 2009 A1
20090062788 Long Mar 2009 A1
20090062792 Vakharia Mar 2009 A1
20090062795 Vakharia Mar 2009 A1
20090076496 Azure Mar 2009 A1
20090076499 Azure Mar 2009 A1
20090076500 Azure Mar 2009 A1
20090076502 Azure Mar 2009 A1
20090081272 Clarke Mar 2009 A1
20090088636 Lau Apr 2009 A1
20090099544 Munrow Apr 2009 A1
20090105703 Shadduck Apr 2009 A1
20090114226 Deem May 2009 A1
20090118725 Auth May 2009 A1
20090118729 Auth May 2009 A1
20090125009 Zikorus May 2009 A1
20090138014 Bonutti May 2009 A1
20090143705 Danek Jun 2009 A1
20090157166 Singhal Jun 2009 A1
20090163904 Miller Jun 2009 A1
20090171280 Samuel Jul 2009 A1
20090177111 Miller Jul 2009 A1
20090186850 Kiribayashi Jul 2009 A1
20090192508 Laufer Jul 2009 A1
20090198227 Prakash Aug 2009 A1
20090204005 Keast Aug 2009 A1
20090204112 Kleyman Aug 2009 A1
20090209955 Forster Aug 2009 A1
20090216543 Pang Aug 2009 A1
20090221939 Demarais Sep 2009 A1
20090228001 Pacey Sep 2009 A1
20090240247 Rioux Sep 2009 A1
20090247933 Maor Oct 2009 A1
20090248012 Maor Oct 2009 A1
20090269317 Davalos Oct 2009 A1
20090270756 Gamache Oct 2009 A1
20090275827 Aiken Nov 2009 A1
20090281477 Mikus Nov 2009 A1
20090281540 Blomgren Nov 2009 A1
20090287081 Grossman Nov 2009 A1
20090292342 Rubinsky Nov 2009 A1
20090301480 Elsakka Dec 2009 A1
20090306544 Ng Dec 2009 A1
20090306545 Elsakka Dec 2009 A1
20090318849 Hobbs Dec 2009 A1
20090318905 Bhargav Dec 2009 A1
20090326366 Krieg Dec 2009 A1
20090326436 Rubinsky Dec 2009 A1
20090326561 Carroll, II Dec 2009 A1
20090326570 Brown Dec 2009 A1
20100006441 Renaud Jan 2010 A1
20100016783 Bourke, Jr. Jan 2010 A1
20100023004 Francischelli Jan 2010 A1
20100030211 Davalos Feb 2010 A1
20100036291 Darlington Feb 2010 A1
20100049190 Long Feb 2010 A1
20100056926 Deckman Mar 2010 A1
20100057074 Roman Mar 2010 A1
20100057076 Behnke Mar 2010 A1
20100069921 Miller Mar 2010 A1
20100079215 Brannan Apr 2010 A1
20100082022 Haley Apr 2010 A1
20100082023 Brannan Apr 2010 A1
20100082024 Brannan Apr 2010 A1
20100082025 Brannan Apr 2010 A1
20100082083 Brannan Apr 2010 A1
20100082084 Brannan Apr 2010 A1
20100087813 Long Apr 2010 A1
20100090696 Deimling Apr 2010 A1
20100100093 Azure Apr 2010 A1
20100106025 Sarfaty Apr 2010 A1
20100106047 Sarfaty Apr 2010 A1
20100121173 Sarfaty May 2010 A1
20100130975 Long May 2010 A1
20100147701 Field Jun 2010 A1
20100152725 Pearson Jun 2010 A1
20100160850 Ivorra Jun 2010 A1
20100168735 Deno Jul 2010 A1
20100174282 Demarais Jul 2010 A1
20100179436 Sarfaty Jul 2010 A1
20100179530 Long Jul 2010 A1
20100191112 Demarais Jul 2010 A1
20100191235 Moshe Jul 2010 A1
20100196984 Rubinsky Aug 2010 A1
20100204560 Salahieh Aug 2010 A1
20100204638 Hobbs Aug 2010 A1
20100211061 Leyh Aug 2010 A1
20100222377 Crooks Sep 2010 A1
20100222677 Placek Sep 2010 A1
20100228234 Hyde Sep 2010 A1
20100228247 Paul Sep 2010 A1
20100241117 Paul Sep 2010 A1
20100249771 Pearson Sep 2010 A1
20100255795 Rubinsky Oct 2010 A1
20100256624 Brannan Oct 2010 A1
20100256628 Pearson Oct 2010 A1
20100256630 Hamilton, Jr. Oct 2010 A1
20100261994 Davalos Oct 2010 A1
20100262067 Chornenky Oct 2010 A1
20100268223 Coe Oct 2010 A1
20100268225 Coe Oct 2010 A1
20100286690 Paul Nov 2010 A1
20100292686 Rick Nov 2010 A1
20100298822 Behnke Nov 2010 A1
20100298823 Cao Nov 2010 A1
20100298825 Slizynski Nov 2010 A1
20100331758 Davalos Dec 2010 A1
20100331911 Kovalcheck Dec 2010 A1
20110009860 Chornenky Jan 2011 A1
20110015630 Azure Jan 2011 A1
20110017207 Hendricksen Jan 2011 A1
20110021970 Vo-Dinh Jan 2011 A1
20110034209 Rubinsky Feb 2011 A1
20110054458 Behnke Mar 2011 A1
20110064371 Leatherman Mar 2011 A1
20110064671 Bynoe Mar 2011 A1
20110082362 Schmidt Apr 2011 A1
20110082414 Wallace Apr 2011 A1
20110092973 Nuccitelli Apr 2011 A1
20110098695 Brannan Apr 2011 A1
20110105823 Single, Jr. May 2011 A1
20110106221 Neal, II May 2011 A1
20110112434 Ghabrial May 2011 A1
20110112531 Landis May 2011 A1
20110118721 Brannan May 2011 A1
20110118727 Fish May 2011 A1
20110118729 Heeren May 2011 A1
20110118732 Rubinsky May 2011 A1
20110118734 Auld May 2011 A1
20110130834 Wilson Jun 2011 A1
20110135626 Kovalcheck Jun 2011 A1
20110144524 Fish Jun 2011 A1
20110144562 Heeren Jun 2011 A1
20110144638 Heeren Jun 2011 A1
20110144641 Dimalanta, Jr. Jun 2011 A1
20110144657 Fish Jun 2011 A1
20110152678 Aljuri Jun 2011 A1
20110152906 Escudero Jun 2011 A1
20110152907 Escudero Jun 2011 A1
20110160514 Long Jun 2011 A1
20110166499 Demarais Jul 2011 A1
20110172659 Brannan Jul 2011 A1
20110176037 Benkley, III Jul 2011 A1
20110178570 Demarais Jul 2011 A1
20110202052 Gelbart Aug 2011 A1
20110202053 Moss Aug 2011 A1
20110207758 Sobotka Aug 2011 A1
20110208096 Demarais Aug 2011 A1
20110208180 Brannan Aug 2011 A1
20110217730 Gazit Sep 2011 A1
20110230874 Epstein Sep 2011 A1
20110245756 Arora Oct 2011 A1
20110251607 Kruecker Oct 2011 A1
20110282354 Schulte Nov 2011 A1
20110288545 Beebe Nov 2011 A1
20110301587 Deem Dec 2011 A1
20110306971 Long Dec 2011 A1
20120034131 Rubinsky Feb 2012 A1
20120046658 Kreindel Feb 2012 A1
20120059255 Paul Mar 2012 A1
20120071870 Salahieh Mar 2012 A1
20120071872 Rubinsky Mar 2012 A1
20120071874 Davalos Mar 2012 A1
20120085649 Sano Apr 2012 A1
20120089009 Omary Apr 2012 A1
20120090643 Bertsch Apr 2012 A1
20120090646 Tanaka Apr 2012 A1
20120095459 Callas Apr 2012 A1
20120101538 Ballakur Apr 2012 A1
20120109122 Arena May 2012 A1
20120130289 Demarais May 2012 A1
20120150172 Ortiz Jun 2012 A1
20120165813 Lee Jun 2012 A1
20120179091 Ivorra Jul 2012 A1
20120220999 Long Aug 2012 A1
20120226218 Phillips Sep 2012 A1
20120226271 Callas Sep 2012 A1
20120265183 Tulleken et al. Oct 2012 A1
20120265186 Burger Oct 2012 A1
20120277741 Davalos Nov 2012 A1
20120303012 Leyh Nov 2012 A1
20120303020 Chornenky Nov 2012 A1
20120310236 Placek Dec 2012 A1
20120310237 Swanson Dec 2012 A1
20130023871 Collins Jan 2013 A1
20130030239 Weyh Jan 2013 A1
20130030430 Stewart Jan 2013 A1
20130033977 Lin Feb 2013 A1
20130035921 Rodriguez-Ponce Feb 2013 A1
20130041436 Ruse Feb 2013 A1
20130072858 Watson Mar 2013 A1
20130090346 Johns Apr 2013 A1
20130090646 Moss Apr 2013 A1
20130108667 Soikum May 2013 A1
20130110103 Assmus May 2013 A1
20130110106 Richardson May 2013 A1
20130184702 Neal, II Jul 2013 A1
20130196441 Rubinsky Aug 2013 A1
20130197425 Golberg Aug 2013 A1
20130202766 Rubinsky Aug 2013 A1
20130218157 Callas Aug 2013 A1
20130230895 Koblizek Sep 2013 A1
20130238062 Ron Edoute Sep 2013 A1
20130253415 Sano Sep 2013 A1
20130261389 Long Oct 2013 A1
20130281968 Davalos Oct 2013 A1
20130296679 Condie Nov 2013 A1
20130338761 Plowiecki Dec 2013 A1
20130345697 Garcia Dec 2013 A1
20130345779 Maor Dec 2013 A1
20140005664 Govari Jan 2014 A1
20140017218 Scott Jan 2014 A1
20140039489 Davalos Feb 2014 A1
20140046322 Callas Feb 2014 A1
20140052118 Laske Feb 2014 A1
20140066913 Sherman Mar 2014 A1
20140081255 Johnson Mar 2014 A1
20140088578 Rubinsky Mar 2014 A1
20140094792 Sharonov Apr 2014 A1
20140094793 Sharonov Apr 2014 A1
20140107643 Chornenky Apr 2014 A1
20140111224 Agate Apr 2014 A1
20140121663 Pearson May 2014 A1
20140121728 Dhillon May 2014 A1
20140163551 Maor Jun 2014 A1
20140207133 Model Jul 2014 A1
20140276748 Ku Sep 2014 A1
20140296844 Kevin Oct 2014 A1
20140309579 Rubinsky Oct 2014 A1
20140378964 Pearson Dec 2014 A1
20150025526 Hua Jan 2015 A1
20150032105 Azure Jan 2015 A1
20150066013 Salahieh Mar 2015 A1
20150066020 Epstein Mar 2015 A1
20150088120 Garcia Mar 2015 A1
20150088220 Callas Mar 2015 A1
20150112333 Chorenky Apr 2015 A1
20150126922 Willis May 2015 A1
20150134584 Nakagawa May 2015 A1
20150141984 Loomas May 2015 A1
20150152504 Lin Jun 2015 A1
20150164584 Davalos Jun 2015 A1
20150173824 Davalos Jun 2015 A1
20150196351 Stone Jul 2015 A1
20150201996 Rubinsky Jul 2015 A1
20150265349 Moss Sep 2015 A1
20150289923 Davalos Oct 2015 A1
20150320478 Cosman, Jr. Nov 2015 A1
20150320481 Cosman, Jr. Nov 2015 A1
20150320488 Moshe Nov 2015 A1
20150320999 Nuccitelli Nov 2015 A1
20150327944 Neal, II Nov 2015 A1
20160022957 Hobbs Jan 2016 A1
20160066977 Neal, II Mar 2016 A1
20160074114 Pearson Mar 2016 A1
20160113708 Moss Apr 2016 A1
20160143398 Kim May 2016 A1
20160143698 Garcia May 2016 A1
20160235470 Callas Aug 2016 A1
20160287313 Rubinsky Oct 2016 A1
20160287314 Arena Oct 2016 A1
20160337310 Faccin Nov 2016 A1
20160338758 Davalos Nov 2016 A9
20160338761 Chornenky Nov 2016 A1
20160354142 Pearson Dec 2016 A1
20160367310 Onik Dec 2016 A1
20170035501 Chornenky Feb 2017 A1
20170065339 Mickelsen Mar 2017 A1
20170137512 Van Hoorick May 2017 A1
20170189579 Davalos Jul 2017 A1
20170209620 Davalos Jul 2017 A1
20170266438 Sano Sep 2017 A1
20170319851 Athos Nov 2017 A1
20170348525 Sano Dec 2017 A1
20170360323 Li Dec 2017 A1
20170360326 Davalos Dec 2017 A1
20180071014 Neal Mar 2018 A1
20180125565 Sano May 2018 A1
20180161086 Davalos Jun 2018 A1
20180198218 Regan Jul 2018 A1
20190023804 Onik Jan 2019 A1
20190029749 Garcia Jan 2019 A1
20190046255 Davalos Feb 2019 A1
20190069945 Davalos Mar 2019 A1
20190076528 Soden Mar 2019 A1
20190083169 Single Mar 2019 A1
20190133671 Davalos May 2019 A1
20190175248 Neal, II Jun 2019 A1
20190175260 Davalos Jun 2019 A1
20190223938 Arena Jul 2019 A1
20190232048 Latouche Aug 2019 A1
20190233809 Neal, II Aug 2019 A1
20190256839 Neal, II Aug 2019 A1
20190282294 Davalos Sep 2019 A1
20190328445 Sano Oct 2019 A1
20190351224 Sano Nov 2019 A1
20190376055 Davalos Dec 2019 A1
20200046432 Garcia Feb 2020 A1
20200046967 Ivey Feb 2020 A1
20200093541 Neal et al. Mar 2020 A9
20200197073 Sano Jun 2020 A1
20200260987 Davalos Aug 2020 A1
20200289188 Forsyth Sep 2020 A1
20200323576 Neal Oct 2020 A1
20200405373 O'Brien Dec 2020 A1
20210022795 Davalos Jan 2021 A1
20210023362 Lorenzo Jan 2021 A1
20210052882 Wasson Feb 2021 A1
20210113265 D'Agostino Apr 2021 A1
20210137410 O'Brien May 2021 A1
20210186600 Davalos Jun 2021 A1
20210361341 Neal, II Nov 2021 A1
20210393312 Davalos Dec 2021 A1
20220151688 Garcia May 2022 A1
20220161027 Aycock May 2022 A1
20220290183 Davalos Sep 2022 A1
20220362549 Sano Nov 2022 A1
20230157759 Garcia May 2023 A1
20230212551 Neal, II Jul 2023 A1
20230248414 Sano Aug 2023 A1
20230355293 Davalos Nov 2023 A1
20230355968 Davalos Nov 2023 A1
Foreign Referenced Citations (188)
Number Date Country
7656800 Apr 2001 AU
2002315095 Dec 2002 AU
2003227960 Dec 2003 AU
2005271471 Feb 2006 AU
2006321570 Jun 2007 AU
2006321574 Jun 2007 AU
2006321918 Jun 2007 AU
2009243079 Jan 2011 AU
2012255070 Jan 2014 AU
2015259303 Nov 2016 AU
2297846 Feb 1999 CA
2378110 Feb 2001 CA
2445392 Nov 2002 CA
2458676 Mar 2003 CA
2487284 Dec 2003 CA
2575792 Feb 2006 CA
2631940 Jun 2007 CA
2631946 Jun 2007 CA
2632604 Jun 2007 CA
2722296 Nov 2009 CA
2751462 Nov 2010 CA
1525839 Sep 2004 CN
101534736 Sep 2009 CN
102238921 Nov 2011 CN
102421386 Apr 2012 CN
106715682 May 2017 CN
112807074 May 2021 CN
833111 Mar 1952 DE
60038026 Feb 2009 DE
60038026 Feb 2009 DE
0218275 Apr 1987 EP
0339501 Nov 1989 EP
0528891 Mar 1993 EP
0533511 Mar 1993 EP
0908156 Apr 1999 EP
0998235 May 2000 EP
1011495 Jun 2000 EP
0528891 Jul 2000 EP
1061983 Dec 2000 EP
1196550 Apr 2002 EP
1207797 May 2002 EP
1344497 Sep 2003 EP
1406685 Apr 2004 EP
1424970 Jun 2004 EP
1439792 Jul 2004 EP
1442765 Aug 2004 EP
1462065 Sep 2004 EP
1061983 Nov 2004 EP
1493397 Jan 2005 EP
1506039 Feb 2005 EP
0935482 May 2005 EP
1011495 Nov 2005 EP
1791485 Jun 2007 EP
1796568 Jun 2007 EP
1207797 Feb 2008 EP
1406685 Jun 2008 EP
1962708 Sep 2008 EP
1962710 Sep 2008 EP
1962945 Sep 2008 EP
1424970 Dec 2008 EP
2280741 Feb 2011 EP
2373241 Oct 2011 EP
2381829 Nov 2011 EP
2413833 Feb 2012 EP
2429435 Mar 2012 EP
2488251 Aug 2012 EP
2593179 May 2013 EP
2627274 Aug 2013 EP
2642937 Oct 2013 EP
2651505 Oct 2013 EP
3143124 Mar 2017 EP
3852868 Jul 2021 EP
2300272 Jun 2008 ES
2315493 Apr 2009 ES
H10243947 Sep 1998 JP
2001510702 Aug 2001 JP
2002360712 Dec 2002 JP
2003505072 Feb 2003 JP
2003506064 Feb 2003 JP
2004203224 Jul 2004 JP
2004525726 Aug 2004 JP
2004303590 Oct 2004 JP
2005501596 Jan 2005 JP
2005526579 Sep 2005 JP
2007516792 Jun 2007 JP
2008508946 Mar 2008 JP
4252316 Apr 2009 JP
4252316 Apr 2009 JP
2009518130 May 2009 JP
2009518150 May 2009 JP
2009518151 May 2009 JP
2009532077 Sep 2009 JP
2009532077 Sep 2009 JP
2010503496 Feb 2010 JP
2010503496 Feb 2010 JP
2010511467 Apr 2010 JP
2011137025 Jul 2011 JP
2012510332 May 2012 JP
2012515018 Jul 2012 JP
2012515018 Jul 2012 JP
2012521863 Sep 2012 JP
2014501574 Jan 2014 JP
2017518805 Jul 2017 JP
6594901 Oct 2019 JP
2019193668 Nov 2019 JP
7051188 Apr 2022 JP
101034682 Apr 2004 KR
9104014 Apr 1991 WO
9614238 May 1996 WO
9634571 Nov 1996 WO
9810745 Mar 1998 WO
9814238 Apr 1998 WO
9901076 Jan 1999 WO
9904710 Feb 1999 WO
0020554 Apr 2000 WO
0110319 Feb 2001 WO
2001048153 Jul 2001 WO
0170114 Sep 2001 WO
0200554 Jan 2002 WO
02078527 Oct 2002 WO
02089686 Nov 2002 WO
02100459 Dec 2002 WO
2003020144 Mar 2003 WO
2003047684 Jun 2003 WO
03099382 Dec 2003 WO
2004008153 Jan 2004 WO
2004080347 Sep 2004 WO
2005065284 Jul 2005 WO
2006017666 Feb 2006 WO
2006031541 Mar 2006 WO
2006130194 Dec 2006 WO
2007067628 Jun 2007 WO
2007067937 Jun 2007 WO
2007067938 Jun 2007 WO
2007067939 Jun 2007 WO
2007067940 Jun 2007 WO
2007067941 Jun 2007 WO
2007067943 Jun 2007 WO
2007070361 Jun 2007 WO
2007100727 Sep 2007 WO
2007123690 Nov 2007 WO
2007137303 Nov 2007 WO
2008034103 Mar 2008 WO
2008063195 May 2008 WO
2008101086 Aug 2008 WO
2008101091 Aug 2008 WO
2009036468 Mar 2009 WO
2009046176 Apr 2009 WO
2009134876 Nov 2009 WO
2009135070 Nov 2009 WO
2009137800 Nov 2009 WO
2010015592 Feb 2010 WO
2010064154 Jun 2010 WO
2010080974 Jul 2010 WO
2010085765 Jul 2010 WO
2010117806 Oct 2010 WO
2010118387 Oct 2010 WO
2010128373 Nov 2010 WO
2010132472 Nov 2010 WO
2010151277 Dec 2010 WO
2011028937 Mar 2011 WO
2011047387 Apr 2011 WO
2011047387 Apr 2011 WO
2011062653 May 2011 WO
2011072221 Jun 2011 WO
2011135294 Nov 2011 WO
2012006533 Jan 2012 WO
2012051433 Apr 2012 WO
2012054560 Apr 2012 WO
2012054573 Apr 2012 WO
2012063266 May 2012 WO
2012071526 May 2012 WO
2012071526 May 2012 WO
2012088149 Jun 2012 WO
2012088149 Jun 2012 WO
2012140376 Oct 2012 WO
2013052138 Apr 2013 WO
2013176881 Nov 2013 WO
2014039320 Mar 2014 WO
2015175570 Nov 2015 WO
2015192027 Dec 2015 WO
2016100325 Jun 2016 WO
2016164930 Oct 2016 WO
2017024123 Feb 2017 WO
2017117418 Jul 2017 WO
2020061192 Mar 2020 WO
2022066768 Mar 2022 WO
2023172773 Sep 2023 WO
Non-Patent Literature Citations (434)
Entry
Sel, D. et al. Sequential finite element model of tissue electropermeabilization. IEEE Transactions on Biomedical Engineering 52, 816-827, doi:10.1109/tbme.2005.845212 (2005).
Sel, D., Lebar, A. M. & Miklavcic, D. Feasibility of employing model-based optimization of pulse amplitude and electrode distance for effective tumor electropermeabilization. IEEE Trans Biomed Eng 54, 773-781 (2007).
Sersa, et al, Tumor blood flow modifying effect of electrochemotherapy with Bleomycin, Anticancer Research, 1999, 19, pp. 4017-4022.
Shafiee, et al, A preliminary study to delineate irreversible electroporation from thermal damage using the Arrhenius equation, Journal of Biomedical Engineering, Jul. 2009, vol. 131, 074509, pp. 1-5.
Shao, Qi et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions, International Journal of Hyperthermia, 2019, DOI: 10.1080/02656736.2018.1539253.
Sharma, A., et al., “Review on Thermal Energy Storage with Phase Change Materials and Applications”, Renewable Sustainable Energy Rev. 13(2), 318-345 (2009).
Soden, et al, Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumors, Cancer Letters, 2006, 232 pp. 300-310.
Son, et al, Basic features of a cell electroporation model: illustrative behavior for tw overy different pulses, J Membrane Biol, Jul. 22, 2014, 247, pp. 1209-1228.
Song, Z.Q., et al., Mechanisms for steep pulse irreversible electroporation technology to kill human large cell lung cancer cells L9981. International Journal of Clinical and Experimental Medicine, 2014. 7(8): p. 2386-2394.
Szot et al., “3D in vitro bioengineered tumors based on collagen I hydrogels.” Biomaterials vol. 32, pp. 7905-7912 (2011).
Talele, S. and P. Gaynor, “Non-linear time domain model of electropermeabilization: Effect of extracellular conductivity and applied electric field parameters”, Journal of Electrostatics,66(5-6): p. 328-334 (2008).
Talele, S. and P. Gaynor, “Non-linear time domain model of electropermeabilization: Response of a single cell to an arbitrary applied electric field”, Journal of Electrostatics, 65(12): p. 775-784 (2007).
Talele, S., et al., “Modelling single cell electroporation with bipolar pulse parameters and dynamic pore radii”. Journal of Electrostatics, 68(3): p. 261-274 (2010).
Teissie, J. and T.Y. Tsong, “Electric-Field Induced Transient Pores in Phospholipid-Bilayer Vesicles”. Biochemistry, 20(6): p. 1548-1554(1981).
Tekle, et al., “Electroporation by using bipolar oscillating electric field: An improved method for DNA transfection of NIF 3T3 cells,” Proc. Natl. Acad. Sci., Biochemistry, vol. 88, pp. 4230-4234, May 1991.
Thomson, Human experience with irreversible electroporation, Irreversible Electroporation, Biomed, 2010, pp. 249-354.
Thomson, K. R., et al., “Investigation of the Safety of Irreversible Electroporation in Humans” J. Vascular Int. Radiol. 22(5), 611-621 (2011).
Tibbitt et al., “Hydrogels as Extracellular Matrix Mimics for 3D Cell Culture”, Jul. 2009, Biotechnol Bioeng, 103(4),655-663.
Tijink, et al, How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients, Correspondence, Clinical Otolaryngology, 2006, 31, pp. 447-451.
Tracy, et al, Irreversible electroporation (IRE): A novel method for renal tissue ablation, BJU International, 107, pp. 1982-1987.
Trimmer, et al, Minimally invasive percutaneous treatment of small renal tumors with irreversible electroporation: a single-center experience, J Vasc Intery Radiol, 2015, 26: pp. 1465-1471.
Troszak, et al., Self-powered electroporation using a singularity-induced nano-electroporation configuration, Biochemical and Biophysical Research Communications, Sep. 28, 2011, 414, pp. 419-424.
Tsivian, Polascik, Recent advances in focal therapy of prostate and kidney cancer, Medicine Reports, Jan. 18, 2010, 2, 1, pp. 1-3.
Valdez, C. M. et al., The interphase interval within a bipolar nanosecond electric pulse modulates bipolar cancellation, Bioelectromagnetics, vol. 39, No. 6,441-450, 2018, 28 pages.
Van Den Bos, W. et al., “MRI and contrast-enhanced ultrasound imaging for evaluation offocal irreversible electroporation treatment: results from a phase i-ii study in patients undergoing ire followed by radical prostatectomy,” European radiology, vol. 26, No. 7, pp. 2252-2260, 2016.
Verbridge et al., “Oxygen-Controlled Three-Dimensional Cultures to Analyze Tumor Angiogenesis.” Tissue Engineering, Part A vol. 16, pp. 2133-2141 (2010).
Verma, A. et al., “Primer on Pulsed Electrical Field Ablation: Understanding the Benefits and Limitations,” Circ. Arrhythmia Electrophysiol., No. September, pp. 1-16,2021,16 pages.
Vernier, P.T., et al., “Nanoelectropulse-driven membrane perturbation and small molecule permeabilization”, Bmc Cell Biology, 7 (2006).
Vi{hacek over (z)}intin, A. et al., “Effect of interphase and interpulse delay in high-frequency irreversible electroporation pulses on cell survival, membrane permeabilization and electrode material release,” Bioelectrochemistry, vol. 134, Aug. 2020,14 Pages.
Voyer, D., A. Silve, L. M. Mir, R. Scorretti, and C. Poignard, “Dynamical modeling of tissue electroporation,” Bioelectrochemistry, vol. 119, pp. 98-110, 2018.
Wandel, A. et al. “Optimizing Irreversible Electroporation Ablation with a Bipolar Electrode,” Journal of Vascular and Interventional Radiology, vol. 27, Issue 9, 1441-1450.e2, 2016.
Wasson, Elisa M. et al. The Feasibility of Enhancing Susceptibility of Glioblastoma Cells to IRE Using a Calcium Adjuvant. Annals of Biomedical Engineering, vol. 45, No. 11, Nov. 2017 pp. 2535-2547.
Weaver et al., “A brief overview of electroporation pulse strength-duration space: A region where additional ntracellular effects are expected.” Bioelectrochemistry vol. 87, pp. 236-243 (2012).
Weaver, J. C., Electroporation of biological membranes from multicellular to nano scales, IEEE Tms. Dielectr. Electr. Insul. 10, 754-768 (2003).
Weaver, J.C., “Electroporation of cells and tissues”, IEEE Transactions on Plasma Science, 28(1): p. 24-33 (2000).
Weisstein: Cassini Ovals. From MathWorld—A. Wolfram Web Resource; Apr. 30, 2010; http://mathworld.wolfram.com/ (updated May 18, 2011) 2 pages.
Wimmer, Thomas, et al., “Planning Irreversible Electroporation (IRE) in the Porcine Kidney: Are Numerical Simulations Reliable for Predicting Empiric Ablation Outcomes?”, Cardiovasc Intervent Radiol. Feb. 2015 ; 38(1): 182-190. doi:10.1007/s00270-014-0905-2.
Wittkampf, et al, Myocardial lesion depth with circular electroporation ablation, Circ Arrhythm Electrophysiol, 2012, 5, pp. 581-586.
Wood et al., Technologies for Guidance of Radiofrequency Ablation in the Multimodality Interventional Suite of the Future, Jan. 2007, National Institutes of Health, pp. 1-26.
Wright, On a relationship between the arrhenius parameters from thermal damage studies, Technical Brief, Journalof Biomechanical Engineering, Transactions of the ASME, Apr. 2003, vol. 125, pp. 300-304.
Yang et al., “Dielectric properties of human leukocyte subpopulations determined by selectrorotation as a cell separation criterion.” Biophysical Journal, vol. 76, pp. 3307-3314 (1999).
Yao et al., “Study of transmembrane potentials of inner and outer membranes induced by pulsed-electric-field model and simulation.” IEEE Trans Plasma Sci, 2007. 35(5): p. 1541-1549.
Yarmush, M. L. et al., “Electroporation-Based Technologies for Medicine: Principles, Applications, and Challenges,” Annu. Rev. Biomed. Eng., vol. 16, No. 1,295-320, 2014, 29 pages.
Ybarra, Gary A, et al. “Breast Imaging using Electrical Impedance Tomography.” in Suri, J.S., R.M. Rangayyan, and S. Laxminarayan, Emerging Technologies in Breast Imaging and Mammography2008: American Scientific Publishers.
Zhang, et al, MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: Preclinical feasibility studies in a rodent model, Radiology, Aug. 2010, vol. 256, No. 2, pp. 424-432.
Zhao, J. et al. “Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer”, Nature Communications (2019) 10:899,14 pages.
Zhao, Y., S. Bhonsle, S. Dong, Y. Lv, H. Liu, A. Safaai-Jazi, R. V. Davalos, and C. Yao, “Characterization of conductivity changes during high-frequency irreversible electroporation for treatment planning,” IEEE Transactions on Biomedical Engineering, vol. 65, No. 8, pp. 1810-1819,2017.
Zhou, et al, Electroporation-mediated transfer of plasmids to the lung results in reduced TLR9 signaling and Inflammation, Gene Therapy, Mar. 8, 2007, 14, pp. 775-780.
Kinosita, Jr., et al., Formation and resealing of pores of controlled sizes in human erythrocyte membrane, Aug. 1977, vol. 268, pp. 438-441.
Kirson et al., “Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.” Proceedings of the National Academy of Sciences vol. 104, pp. 10152-10157 (2007).
Knight, et al, Direct imaging of transvenous radiofrequency cardiac ablation using a steerable fiberoptic infrared endoscope, Heart Rhythm Society, Oct. 2005, vol. 2, No. 10, pp. 1116-1121.
Kolb, J.F., et al., “Nanosecond pulsed electric field generators for the study of subcellular effects”, Bioelectromagnetics, 27(3): p. 172-187 (2006).
Kotnik and Miklavcic, “Theoretical evaluation of voltage inducement on internal membranes of biological cells exposed o electric fields.” Biophysical Journal, vol. 90(2), pp. 480-491 (2006).
Kotnik et al., “Sensitivity of transmembrane voltage induced by applied electric fields—A theoretical analysis”, Bioelectrochemistry and Bioenergetics, vol. 43, Issue 2, 1997, pp. 285-291.
Kotnik, T. and D. Miklavcic, “Theoretical evaluation of the distributed power dissipation in biological cells exposed to electric fields”, Bioelectromagnetics, 21(5): p. 385-394 (2000).
Kotnik, T., et al., “Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses”. Part I. Increased efficiency of permeabilization. Bioelectrochemistry, 54(1): p. 83-90 (2001).
Kotnik, T., et al., “Role of pulse shape in cell membrane electropermeabilization”, Biochimica Et Biophysica Acta-iomembranes, 1614(2): p. 193-200 (2003).
Kotnik, T., et al., “Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses. Part II. Reduced electrolytic contamination”, Bioelectrochemistry, 54(1): p. 91-95 (2001).
Kranjc, M., S. Kranjc, F. Bajd, G. Sersa, I. Sersa, and D. Miklav{hacek over (c)}i{hacek over (c)}, “Predicting irreversible electroporation-induced tissue damage by means of magnetic resonance electrical impedance tomography,” Scientific reports, vol. 7, No. 1, pp. 1-10, 2017.
Kroeger, et al, Curvature-driven pore growth in charged membranes during charge-pulse and voltage-clamp experiments, Biophysical Journal, Feb. 2009, 96, 3, pp. 907-916.
Kurup, et al, Image-Guided Percutaneous Ablation of Bone and soft Tissue Tumors, Semin Intervent Radiol 2010, 27:276-284.
Labeed et al., “Differences in the biophysical properties of membrane and cytoplasm of apoptotic cells revealed using dielectrophoresis.” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1760, pp. 922-929 (2006).
Lackovic, I., et al., “Three-dimensional Finite-element Analysis of Joule Heating in Electrochemotherapy and in vivo Gene Electrotransfer”, Ieee Transactions on Dielectrics and Electrical Insulation, 16(5): p. 1338-1347 (2009).
Laufer, et al., Electricai impedance characterization of normal and cancerous human hepatic tissue, Physicological Measurement, vol. 31, pp. 995-1009 (2010).
Lavee, et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1201, vol. 10 (2): 96-101 (2007).
Lebar et al., “Inter-pulse interval between rectangular voltage pulses affects electroporation threshold of artificial lipid bilayers.” IEEE Transactions on Nano Bioscience, vol. 1 (2002) pp. 116-120.
Lee, Cassinian Oval, Nov. 2004, Mathematics Department of the University of California at Irvine, pp. 1-5.
Lee, E. W. et al. Advanced Hepatic Ablation Technique for Creating Complete Cell Death : Irreversible Electroporation. Radiology 255, 426-433, doi:10.1148/radiol. 10090337 (2010).
Lee, et al, Imaging guided percutaneous irreversible electroporation: Ultrasound and immunohistological correlation, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 287-293.
Lee, et al, Irreversible electroporation: A novel image-guided cancer therapy, Gut and Liver, Sep. 2010, vol. 4, Supp. 1, pp. S99-S104.
Lee, R. C., D. J. Canaday, and S. M. Hammer. Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J. Burn Care Rehabil. 14:528-540,1993.
Li, et al, The effects of irreversible electroporation (IRE) on nerves, PLOS One, Apr. 14, 2011, vol. 6, Iss. 4, e18831, pp. 1-7.
Lin, et al., An optically induced cell lysis device using dielectrophoresis, Applied Physics Letters, Jan. 20, 2009, 94, 033901, pp. 1-3.
Lion, et al, Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC, PLOS One, vol. 6, Iss. 6, e20952, pp. 1-10, Jun. 17, 2011.
Long, G., et al., “Targeted Tissue Ablation With Nanosecond Pulses”, Ieee Transactions on Biomedical Engineering, 58(8) (2011).
Lu, et al, Irreversible electroporation: Ready for prime time?, Techniques in Vascular and Interventional Radiology, 2013, 16, pp. 277-286.
Ivorra, A., ed. “Tissue Electroporation as a Bioelectric Phenomenon: Basic Concepts. Irreversible Electroporation”, ed. B. Rubinsky., Springer Berlin Heidelberg. 23-61 (2010).
M. Marty et al., “Electrochemotherapy—An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study,” European Journal of Cancer Supplements, 4, pp. 3-13, 2006.
Macek Lebar and Miklavcic, “Cell electropermeabilization to small molecules in vitro: control by pulse parameters.” Radiology and Oncology, vol. 35(3), pp. 193-202 (2001).
Machado-Aranda, et al, Gene transfer of the Na+, K+K-ATPase B1 subunit using electroporation increases lung liquid clearance, American Journal of Respiratory and Critical Care Medicine, 2004, vol. 171, pp. 204-211.
Macherey, O. et al., “Asymmetric pulses in cochlear implants: Effects of pulse shape, polarity, and rate,” JARO—J. Assoc. Res. Otolaryngol., vol. 7, No. 3, 253-266, 2006, 14 pages.
Mahmood, F., et al., “Diffusion-Weighted MRI for Verification of Electroporation-Based Treatments”, Journal of Membrane Biology 240:131-138 (2011).
Mahmood, Gehl, Optimizing clinical performance and geometrical robustness of a new electrode device for ntracranial tumor electroporation, Bioelectrochemistry, Jan. 6, 2011, 81, pp. 10-16.
Mahnic-Kalamiza, et al., “Educational application for visualization and analysis of electric field strength in multiple electrode electroporation,” BMC Med Educ, vol. 12:102,13 pages, 2012.
Mali, et al., “The Effect of Electroporation Pulses on Functioning of the Heart,” Med Biol Eng Comput (2008) 46:745-757.
Malpica et al., “Grading ovarian serous carcinoma using a two-tier system.” The American Journal of Surgical Pathology, vol. 28, pp. 496-504 (2004).
Maor et al., The Effect of Irreversible Electroporation on Blood Vessels, Tech, in Cancer Res. and Treatment, vol. 6, No. 4, Aug. 2007, pp. 307-312.
Maor, et al, Intravascular irreversible electroporation: Theoretical and experimental feasibility study, 30th Annual International IEEE EMBS Conference, IEEE, Aug. 20, 2008, pp. 2051-2054.
Maor, et al, Irreversible electroporation attenuates neointimal formation after angioplasty, IEEE Transactions on Biomedical Engineering, Sep. 2008, vol. 55, No. 9, pp. 2268-2274.
Maor, et al., Non Thermal Irreversible Electroporation: Novel Technology for Vascular Smooth Muscle Cells Ablation, PLoS One, Mar. 2009, 4(3): p. e4757, 9 pages.
Maor, Rubinsky, Endovascular nonthermal irreversible electroporation: A finite element analysis, Journal of Biomedical Engineering, Feb. 7, 2010, vol. 132, 031008, pp. 1-7.
Marszalek et al., “Schwan equation and transmembrane potential induced by alternating electric field.” Biophysical Journal, vol. 58, pp. 1053-1058 (1990).
Martin et al., “Gene Transfer to Intact Mesenteric Arteries by Electroporation” Journal of Vascular Research, 37:372-380 (2000).
Martin, n.R.C.G., et al., “Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.” Journal of the American College of Surgeons, 2012.215(3): p. 361-369.
Martinsen, O. G. and Grimnes, S., Bioimpedance and bioelectricity basics. Academic press, 2011.
Maybody, An Overview of Image-Guided Percutaneous Ablation of Renal Tumors, Seminars in Interventional Radiology/vol. 27, No. 3, 2010, pp. 261-267.
Mazurek, et al, Effect of Short HV Pulses in Bacteria and Fungi, 1995, vol. 2, No. 3, pp. 418-425.
McCall, Nanoknife, liposomal doxorubicin show efficacy against liver cancer, European Congress of Radiology, Mar. 1, 2011, pp. 1-2.
Abiror, I.G., et al., “Electric Breakdown of Bilayer Lipid-Membranes .1. Main Experimental Facts and Their Qualitative Discussion”, Bioelectrochemistry and Bioenergetics, 6(1): p. 37-52 (1979).
Adeyanju, et al, The improvement of irreversible electroporation therapy using saline-irrigated electrodes: A theoretical study, Technology in Cancer Research and Treatment, Aug. 2011, vol. 10, No. 4, pp. 347-360.
Agerholm-Larsen, B., et al., “Preclinical Validation of Electrochemotherapy as an Effective Treatment for Brain Trumors”, Cancer Research 71: 3753-3762 (2011).
Al-Khadra, et al, The role of electroporation in defibrillation, Circulation Research, Oct. 27, 2000, 87, pp. 797-804.
Al-Sakere et al., “Tumor ablation with irreversible electroporation.” PLoS One, Issue 11, e1135, 8 pages, 2007.
Al-Sakere, et al, A study of the immunological response to tumor ablation with irreversible electroporation, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 301-305.
Albright, et al, Performance and complicatioins associated with the Synchromed 10-ml infusion pump for intrathecal baclofen administration in children, J Neurosurg (Pediatrics 2), Aug. 2004, vol. 101, pp. 64-68.
Alinezhadbalalami, N. et al., “Generation of Tumor-activated T cells Using Electroporation”, Bioelectrochemistry 142 (2021) 107886, Jul. 13, 2021, 11 pages.
Appelbaum et al., “US Findings after Irreversible Electroporation Ablation: Radiologic-Pathologic Correlation,” Radiology, 262, pp. 117-125, Jan. 1, 2012.
Arena et al. “High-Frequency Irreversible Electroporation (H-FIRE) for Non-thermal Ablation without Muscle Contraction.” Biomed. Eng. Online, vol. 10, 20 pages (2011).
Arena, C. B. et al., “Theoretical Considerations of Tissue Electroporation With High-Frequency Bipolar Pulses,” IEEE Trans. Biomed. Eng., vol. 58, No. 5, 1474-1482, 2011, 9 pages.
Arena, C.B., et al., “A three-dimensional in vitro tumor platform for modeling therapeutic irreversible electroporation.” Biophysical Journal, 2012.103(9): p. 2033-2042.
Arena, Christopher B., et al.,“Phase Change Electrodes for Reducing Joule Heating During Irreversible Electroporation”. Proceedings of the ASME 2012 Summer Bioengineering Conference, SBC2012, Jun. 20-23, 2012, Fajardo, Puerto Rico.
Arena, et al, Theoretical considerations of tissue electropration with high frequency biopolar pulses, IEEEE, pp. 1-7, (2010).
Arena, et al, Towards the development of latent heat storage electrodes for electroporation-based therapies, Applied Physics Letters, 2012, 101, 083902, pp. 1-4.
Asami et al., “Dielectric properties of Aouse lyAphocytes and erythrocytes.” BiochiAica et Biophysica Acta (BBA)—Molecular Cell Research, 1010 (1989) pp. 49-55.
Bolland, F., et al., “Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering”, Biomaterials, Elsevier Science Publishers, Barking, GB, vol. 28, No. 6,Nov. 28, 2006, pp. 1061-1070.
Bagla, S. and Papadouris, D., “Percutaneous Irreversible Electroporation of Surgically Unresectable Pancreatic Cancer: A Case Report” J. Vascular Int. Radiol. 23(1), 142-145 (2012).
Ball, et al, Irreversible electroporation: A new challenge in “out of the operating theater” anesthesia, Anesth Analg, May 2010, 110, pp. 1305-1309.
Bancroft, et al., Design of a Flow Perfusion Bioreactor SysteA for Bone Tissue-Engineering Applications, Tissue Engineering, vol. 9, No. 3, 2003, p. 549-554.
Baptista et al., “The Use of Whole Organ Decellularization for the Generation of a Vascularized Liver Organoid,” Heptatology, vol. 53, No. 2, pp. 604-617 (2011).
Bayazitoglu, et al, An overview of nanoparticle assisted laser therapy, International Journal of Heat and Mass Transfer, Sep. 11, 2013, 67, pp. 469-486.
Beebe, S.J., et al., “Diverse effects of nanosecond pulsed electric fields on cells and tissues”, DNA and Cell Biology, 22(12): 785-796(2003).
Beebe, S.J., et al.,, “Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells”, FASEB J, 17(9): p. 1493-5 (2003).
Beitel-White, N., S. Bhonsle, R. Martin, and R. V. Davalos, “Electrical characterization of human biological tissue or irreversible electroporation treatments,” in 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2018, pp. 4170-4173.
Belehradek, J., et al., “Electropermeabilization of Cells in Tissues Assessed by the Qualitative and Quantitative Electroloading of Bleomycin”, Biochimica Et Biophysica Acta—Biomembranes, 1190(1): p. 155-163 (1994).
Ben-David, E. et al., “Irreversible Electroporation: Treatment Effect is Susceptible to Local Environment and Tissue Properties,” Radiology, vol. 269, No. 3, 2013, 738-747.
Ben-David, E.,et al., “Characterization of Irreversible Electroporation Ablation in In Vivo Procine Liver” Am. J. Roentgenol. 198(1), W62-W68 (2012).
Benz, R., et al. “Reversible electrical breakdown of lipid bilayer membranes: a charge-pulse relaxation study”. J Membr Biol, 48(2): p. 181-204 (1979).
Bertacchini, et al, Design of an irreversible electroporation system for clinical use, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 313-320.
Bhonsle, S. et al., “Characterization of Irreversible Electroporation Ablation with a Validated Perfused Organ Model,” J. Vase. Interv. Radiol., vol. 27, No. 12, pp. 1913-1922.e2, 2016.
Bhonsle, S. P. et al., “Mitigation of impedance changes due to electroporation therapy using bursts of high-frequency bipolar pulses,” Biomed. Eng. (NY)., vol. 14, No. Suppl 3, 14 pages, 2015.
Bhonsle, S., M. F. Lorenzo, A. Safaai-Jazi, and R. V. Davalos, “Characterization of nonlinearity and dispersion in issue impedance during high-frequency electroporation,” IEEE Transactions on Biomedical Engineering, vol. 65, No. 10, pp. 2190-2201,2018.
Bonakdar, M., E. L. Latouche, R. L. Mahajan, and R. V. Davalos, “The feasibility of a smart surgical probe for verification of IRE treatments using electrical impedance spectroscopy,” IEEE Trans. Biomed. Eng., vol. 62, No. 11, pp. 2674-2684, 2015.
Bondarenko, A. and G. Ragoisha, Eis spectrum analyser (the program is available online at http://www.abc.chemistry.bsu.by/vi/analyser/.
Boone, et al, Review imaging with electricity: Report of the European concerted action on impedance tomography, Journal of Medical Engineering & Technology, Nov. 1997, vol. 21, No. 6, pp. 201-232.
Boussetta, N., N. Grimi, N. I. Lebovka, and E. Vorobiev, “Cold” electroporation in potato tissue induced by pulsed electric field, Journal of food engineering, vol. 115, No. 2, pp. 232-236,2013.
Bower et al., “Irreversible electroporation of the pancreas: definitive local therapy without systemic effects.” Journal of surgical oncology, 2011.104(1): p. 22-28.
Buist et al., “Efficacy of multi-electrode linear irreversible electroporation,” Europace, vol. 23, No. 3, pp. 464-468, 2021, 5 pages.
Bulvik, B. E. et al. “Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small Animal Model,” Radiology, vol. 280, No. 2, 2016,413-424.
Butikofer, R. et al., “Electrocutaneous Nerve Stimulation-I: Model and Experiment,” IEEE Trans. Biomed. Eng., vol. BME-25, No. 6, 526-531, 1978,6 pages.
Butikofer, R. et al., “Electrocutaneous Nerve Stimulation-II: Stimulus Waveform Selection,” IEEE Trans. Biomed. Eng., vol. BME-26, No. 2, 69-75, 1979.
Cannon et al., “Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures.” Journal of Surgical Oncology, 6 pages (2012).
Carmi, and Georgiades, Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: A review, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 296-301.
Carpenter A.E. et al., “CellProfiler: image analysis software for identifying and quantifying cell phenotypes.” Genome Biol. 2006; 7(10): R100. Published online Oct. 31, 2006,11 pages.
Castellvi, Q., B. Mercadal, and A. Ivorra, “Assessment of electroporation by electrical impedance methods,” in Handbook of electroporation. Springer-Verlag, 2016, pp. 671-690.
Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, et al., “Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy”, Br J Cancer 84: 565-570 (2001).
Chang, D.C., “Cell Poration and Cell-Fusion Using an Oscillating Electric-Field”. Biophysical Journal, 56(4): p. 641-652(1989).
Charpentier, et al, Irreversible electroporation of the liver an dliver hilum in swine, HBP, 2011, 13, pp. 168-173.
Charpentier, K.P., et al., “Irreversible electroporation of the pancreas in swine: a pilot study.” HPB: the official journal of the International Hepato Pancreato Biliary Association, 2010.12(5): p. 348-351.
PCT Application No. PCT/US2011/062067, International Search Report and Written Opinion dated Jul. 25, 2012.
PCT Application No. PCT/US2011/066239, International Search Report (dated Aug. 22, 2012), and Written Opinion (dated Aug. 22, 2012).
PCT International Search Report and Written Opinion from PCT/US2010/053077, dated Aug. 2, 2011.
PCT International Search Report for PCT/US10/29243 dated Jul. 30, 2010, 4 pages.
Pech, et al, Irreversible electroporation of renal cell carcinoma: A first-in-man phase I clinical study, Cardiovasc Intervent Radiol, Aug. 15, 2010.
Persichetti F et al, “Normal and Expanded Huntington's Disease Gene Alleles Produce Distinguishable Proteins Due to Translation Across the CAG Repeat”, Molecular Medicine, Feinstein Institute for Medical Research, Washington, DC; US, (May 1, 1995), vol. 1, No. 4, ISSN 1076-1551, pp. 374-383, XP000997528.
Philips, IntelliVue Patient Monitor, Jan. 2008, Philips, pp. 1-532 (Year: 2008).
Phillips, et al, Irreversible electroporation on the small intestine, British Journal of Cancer, 2012, pp. 1-6.
Phillips, et al, Nonthermal irreversible electroporation for tissue decellularization, Journal of Biomedical Engineering, Aug. 16, 2010, vol. 132, 091003, pp. 1-8.
Polajzer, T. et al., “Cancellation effect is present in high-frequency reversible and irreversible electroporation,” Bioelectrochemistry, vol. 132, 2020, 11 pages.
Polak, et al, On the electroporation thresholds of lipid bilayers: Molecular dynamics simulation investigations, J Membrane Biol, Jun. 13, 2013, 246, pp. 843-850.
Pucihar et al., “Numerical determination of transmembrane voltage induced on irregularly shaped cells.” Annals of Biomedical Engineering, vol. 34, pp. 642-652 (2006).
Qiao et al. Electrical properties of breast cancer cells from impedance measurement of cell suspensions, 2010, Journal of Physics, 224, 1-4 (2010).
Radeva, et al, Induction of apoptosis and necrosis in cancer cells by electric fields, electromagnetic fields, and photodynamically active quinoids, Electromagnetic Biology and Medicine, 2003, 23, pp. 185-200.
Rajagopal, V. and S.G. Rockson, Coronary restenosis: a review of mechanisms and management, The American Journal of Medicine, 2003, 115(7): p. 547-553.
Rebersek, et al., Advantages and disadvantages of different concepts of electroporation pulse generation, Automatika, 2011, 52, 1, pp. 12-19.
Reilly, J. P. et al., “Sensory Effects of Transient Electrical Stimulation-Evaluation with a Neuroelectric Model,” IEEE Trans. Biomed. Eng., vol. BME-32, No. 12, 1001-1011, 1985, 11 pages.
Ringel-Scaia, V. M. et al., High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity. EBioMedicine, 2019,44,112-125.
Rogers, W. R. et al., “Strength-duration curve an electrically excitable tissue extended down to near 1 nanosecond,” IEEE Trans. Plasma Sci., vol. 32, No. 4 II, 1587-1599, 2004, 13 pages.
Ron et al., “Cell-based screening for membranal and cytoplasmatic markers using dielectric spectroscopy.” Biophysical chemistry, 135 (2008) pp. 59-68.
Rossmeisl et al., “Pathology of non-thermal irreversible electroporation (N-TIRE)-induced ablation of the canine brain.” Journal of Veterinary Science vol. 14, pp. 433-440 (2013).
Rossmeisl, “New Treatment Modalities for Brain Tumors in Dogs and Cats.” Veterinary Clinics of North America: Small Animal Practice 44, pp. 1013-1038 (2014).
Rossmeisl, John H. et al. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas. J. Neurosurgery 123.4 (2015): 1008-1025.
Rowland, et al, Transvenous ablation of atrioventricular conduction with a low energy power source, Br Heart J, 1989, 62, pp. 361-366.
Rubinsky, B., “Irreversible Electroporation in Medicine”, Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. 1, 2007, pp. 255-259.
Rubinsky, et al, Optimal parameters for the destruction of prostate cancer using irreversible electroporation, The Journal of Urology, Dec. 2008, vol. 180, pp. 2668-2674.
Rubinsky, L. et al., “Electrolytic Effects During Tissue Ablation by Electroporation,” Technol. Cancer Res. Treat., vol. 15, No. 5, NP95-103, 2016, 9 pages.
Sabuncu, et al, Dielectrophoretic separation of mouse melanoma clones, Biomicrofluidics, Jun. 16, 2010, 4, 021101, pp. 1-7.
SAI Infusion Technologies, “Rabbit Ear Vein Catheters”, https://www.sai-infusion.com/products/rabbit-ear-catheters, Aug. 10, 2017 webpage printout, 5 pages.
Saldanha, et al, Current tumor ablation technologies: Basic science and device review, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 247-254.
Salford, L.G., et al., “A new brain tumour therapy combining bleomycin with in vivo electropermeabilization”, Biochem. Biophys. Res. Commun., 194(2): 938-943 (1993).
Salmanzadeh et al., “Investigating dielectric properties of different stages of syngeneic murine ovarian cancer cells” Biomicrofiuidics 7, 011809 (2013), 12 pages.
Salmanzadeh et al., “Sphingolipid Metabolites Modulate Dielectric Characteristics of Cells in a Mouse Ovarian Cancer Progression Model.” Integr. Biol., 5(6). pp. 843-852 (2013).
Salmanzadeh et al.,“Dielectrophoretic differentiation of mouse ovarian surface epithelial cells, macrophages, and fibroblasts using contactless dielectrophoresis.” Biomicrofluidics, vol. 6,13 Pages (2012).
Sanchez, B., G. Vandersteen, R. Bragos, and J. Schoukens, “Basics of broadband impedance spectroscopy measurements using periodic excitations,” Measurement Science and Technology, vol. 23, No. 10, p. 105501, 2012.
Sanchez, B., G. Vandersteen, R. Bragos, and J. Schoukens, “Optimal multisine excitation design for broadband electrical impedance spec-troscopy,” Measurement Science and Technology, vol. 22, No. 11, p. 115601,2011.
Sanders, et al., Nanosecond pulse generator with scalable pulse amplitude, IEEE, 2008, pp. 65-68.
Sankaranarayanan, et al, Effect of irreversible electroporation on cell proliferation in fibroblasts, Proc. ESA Annual Meeting on Electrostatics, 2011, pp. 1-8.
Sano et al., “In-vitro bipolar nano- and microsecond electro-pulse bursts for irreversible electroporation therapies.” Bioelectrochemistry vol. 100, pp. 69-79 (2014).
Sano et al., “Modeling and Development of a Low Frequency Contactless Dielectrophoresis (cDEP) Platform to Sort cancer Cells from Dilute Whole Blood Samples.” Biosensors & Bioelectronics, 8 pages (2011).
Sano et al., “Contactless Dielectrophoretic Spectroscopy: Examination of the Dielectric Properties of Cells Found in Blood.” Electrophoresis, 32, pp. 3164-3171, 2011.
Sano, et al, Towards the creation of decellularized organ constructs using irreversible electroporation and active mechanical perfusion, Biomedical Engineering Online, 2010, 9, 83, pp. 1-16.
Sano, M. B. et al., “Reduction of Muscle Contractions During Irreversible Electroporation Therapy Using High-Frequency Bursts of Alternating Polarity Pulses: A Laboratory Investigation in an Ex Vivo Swine Model,” J. Vase, interv. Radiol., vol. 29, No. 6, 893-898.e4, Jun. 2018, 18 pages.
Sano, M. B. et al., “Burst and continuous high frequency irreversible electroporation protocols evaluated in a 3D tumor Model,” Phys. Med. Biol., vol. 63, No. 13, 2018,17 pages.
Saur et al., “CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer.” Gastroenterology, vol. 129, pp. 1237-1250 (2005).
Savader, et al.“Treatment of Hemodialysis Catheter-associated Fibrin Sheaths by rt-PA Infusion: Critical Analysis of 124 Procedures,” J Vasc Intery Radiol 2001; 12:711-715.
Schoenbach et al., “Intracellular effect of ultrashort electrical pulses.” Bioelectromagnetics, 22 (2001) pp. 440-448.
Schoenbach, et al, Bioelectric effects of intense nanosecond pulses, IEEE Transactions on Dielectric and Electrical Insulation, 2007, vol. 14, Iss. 5, pp. 1088-1109.
Seibert et al., “Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.” Cancer Research, vol. 13, pp. 2223-2239 (1983).
Seidler et al., “A Cre-IoxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors.” Proceedings of the National Academy of Sciences, vol. 105, pp. 10137-10142 (2008).
Chen et al., “Classification of cell types using a microfluidic device for mechanical and electrical measurement on single cells.” Lab on a Chip, vol. 11, pp. 3174-3181 (2011).
Chen, et al, Preclinical study of locoregional therapy of hepatocellular carcinoma by bioelectric ablation with microsecond pulsed electric fields (usPEFs), Scientific Reports, Apr. 2015, 5, 9851, pp. 1-10.
Chen, M.T., et al., “Two-dimensional nanosecond electric field mapping based on cell electropermeabilization”, PMC Biophys, 2(1 ):9 (2009).
Choi, et al, Preclinical analysis of irreversible electroporation on rat liver tissues using a microfabricated electroporator, Tissue Engineering Part C, 2010, vol. 16, No. 6, pp. 1245-1253.
Clark et al., “The electrical properties of resting and secreting pancreas.” The Journal of Physiology, vol. 189, pp. 247-260 (1967).
Corovic, et al, Analytical and numerical quantification and comparison of the local electric field in the tissue for different electrode configurations, BioMedical Engineering Online, Oct. 15, 2007, 6, 37, pp. 1-14.
Cosman, E. R. et al., “Electric and Thermal Field Effects in Tissue Around Radiofrequency Electrodes,” Pain Med., vol. 6, No. 6, 405-4124, 2005, 20 pages.
Craiu, Scadden, Chapter 22 flow electroporation with pulsed electric fields for purging tumor cells, Electroporation Protocols: Preclinical and Clinical Gene Medicine, Methods in Molecular Biology, vol. 423, 2008, pp. 301-310.
Creason, S. O, J. W. Hayes, and D. E. Smith, “Fourier transform faradaic admittance measurements iii. comparison pf measurement efficiency for various test signal waveforms,” Journal of Electroanalytical chemistry and interfacial electrochemistry, vol. 47, No. 1, pp. 9-46,1973.
Cukjati, et al, Real time electroporation control for accurate and safe in vivo non-viral gene therapy, Bioelectrochemistry, Nov. 10, 2006, 70, pp. 501-507.
Dahl et al., “Nuclear shape, mechanics, and mechanotransduction.” Circulation Research vol. 102, pp. 1307-1318 (2008).
Daniels, Rubinsky, Electrical field and temperature model of nonthermal irreversible electroporation in heterogeneous tissues, Journal of Biomedical Engineering, Jul. 2009, vol. 131, 071006, pp. 1-12.
Daniels, Rubinsky, Temperature modulation of electric fields in biological matter, PLOS One, vol. 6, Iss. 6, e20877, pp. 1-9, Jun. 2011.
Daskalov, I., et al, “Exploring new instrumentation parameters for electrochemotherapy—Attacking tumors with bursts of biphasic pulses instead of single pulses”, IEEE Eng Med Biol Mag, 18(1): p. 62-66 (1999).
Daud, A.I., et al., “Phase 1 Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma,” Journal of Clinical Oncology, 26, 5896-5903, Dec. 20, 2008.
Davalos et al., “Electrical impedance tomography for imaging tissue electroporation,” IEEE Transactions on Biomedical Engineering, 51, pp. 761-767, 2004.
Davalos, R. V. & Rubinsky, B. Temperature considerations during irreversible electroporation. International Journal of Heat and Mass Transfer 51, 5617-5622, doi:10.1016/j.ijheatmasstransfer.2008.04.046 (2008).
De Senneville, B. D. et al., “MR thermometry for monitoring tumor ablation,” European radiology, vol. 17, No. 9, pp. 2401-2410, 2007.
De Vuyst, E., et al., “In situ bipolar Electroporation for localized cell loading with reporter dyes and investigating gap functional coupling”, Biophysical Journal, 94(2): p. 469-479 (2008).
Demirbas, M. F., “Thermal Energy Storage and Phase Change Materials: An Overview” Energy Sources Part B 1(1), 35-95 (2006).
Deodhar, et al, Irreversible electroporation near the heart: Ventricular arrhythmias can be prevented with ECG synchronization, AJR, Mar. 2011, 196, pp. W330-W335.
Deodhar, et al, Renal tissue ablation with irreversible electroporation: Preliminary results in a porcine model, Technology and Engineering, Urology, 2010, 1-7.
Dev, et al, Electric field of a six-needle array electrode used in drug and DNA delivery in vivo: Analytical versus numerical solution, IEEE Transactions on Biomedical Engineering, Nov. 2003, vol. 50, No. 11, pp. 1296-1300.
Diederich, et al, Catheter-based ultrasound applicators for selective thermal ablation: progress towards MRI-guided applications in prostate, Int. J. Hyperthermia, Nov. 2004, vol. 20, No. 7, pp. 739-756.
Du Pre, et al, Minimal coronary artery damage by myocardial electroporation ablation, European Society of Cardiology, Europace, May 31, 2012, pp. 1-6.
Duck, F. A., Physical Properties of Tissue: A Comprehensive Reference Book. London: Harcourt Brace Jovanovich, 1990.
Dunki-Jacobs, et al, Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas, American College of Surgeons, Feb. 2014, vol. 218, No. 2, pp. 179-187.
Dupuy, and Shulman, Current status of thermal ablation treatments for lung malignancies, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 268-275.
Dupuy, et al, Irreversible electroporation in a swine lung model, Cardiovasc Intervent Radiol, Dec. 30, 2010, 34, pp. 391-395.
Edd, J.F, et al., 2007, “Mathematical modeling of irreversible electroporation fortreatment planning.”, Technology in Cancer Research and Treatment, 6:275-286.
Ellis TL, Garcia PA, Rossmeisl JH, Jr., Henao-Guerrero N, Robertson J, et al., “Nonthermal irreversible electroporatior for intracranial surgical applications. Laboratory investigation”, J Neurosurg 114: 681-688 (2011).
Eppich et al., “Pulsed electric fields for selection of hematopoietic cells and depletion of tumor cell contaminants.” Nature Biotechnology 18, pp. 882-887 (2000).
Ermolina et al., “Study of normal and malignant white blood cells by time domain dielectric spectroscopy.” IEEE Transactions on Dielectrics and Electrical Insulation, 8 (2001) pp. 253-261.
Esser, A.T., et al., “Towards solid tumor treatment by irreversible electroporation: intrinsic redistribution of fields and currents in tissue”. Technol Cancer Res Treat, 6(4): p. 261-74 (2007).
Esser, A.T., et al., “Towards Solid Tumor Treatment by Nanosecond Pulsed Electric Fields”, Technology in Cancer Research & Treatment, 8(4): p. 289-306 (2009).
Faroja, et al, Irreversible electroporation ablation: Is all the damage nonthermal?, Radiology, Feb. 2013, vol. 266, No. 2, pp. 462-470.
Fischbach, et al, Engineering tumors with 3D scaffolds, Nature Methods, Sep. 2, 2007, vol. 4, No. 10, pp. 855-860.
Flanagan et al., “Unique dielectric properties distinguish stem cells and their differentiated progeny.” Stem Cells, vol. 26, pp. 656-665 (2008).
Fong et al., “Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.” Proceedings of the National Academy of Sciences vol. 110, pp. 6500-6505 (2013).
Foster, R.S., et al., Production of Prostatic Lesions in Canines Using Transrectally Administered High-Intensity Focused Ultrasound. Eur. Urol., 1993; 23: 330-336.
Frandsen, S. K., H. Gissel, P. Hojman, T. Tramm, J. Eriksen, and J. Gehl. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res. 72:1336-41,2012.
Freeman, S.A., et al., Theory of Electroporation of Planar Bilayer-Membranes—Predictions of the Aqueous Area, Change in Capacitance, and Pore-Pore Separation. Biophysical Journal, 67(1): p. 42-56 (1994).
Gabriel, C, Dielectric properties of biological tissue: variation with age. Bioelectromagnetics, 2005. Suppl 7: p. S12-8.
Garca-Sánchez, T., A. Azan, I. Leray, J. Rosell-Ferrer, R. Bragos, and L. M. Mir, “Interpulse multifrequency electrical Impedance measurements during electroporation of adherent differentiated myotubes,” Bioelectrochemistry, vol. 105, pp. 123-135, 2015.
Garcia et al., “Irreversible electroporation (IRE) to treat brain cancer.” ASME Summer Bioengineering Conference, Marco Island, FL, Jun. 25-29, 2008, 2 pages.
Garcia et al., “Towards a Predictive Model of Electroporation-Based Therapies using Pre-Pulse Electrical Measurements” Abstract presented in the IEEE Engineering in Medicine and Biology Conference in Aug. 28, 2012 in San Diego, California, 4 pages.
Garcia P.A., et al., “Pilot study of irreversible electroporation for intracranial surgery”, Conf Proc IEEE Eng Med Biol Soc, 2009:6513-6516, 2009.
Garcia P.A., et al., “7.0-T Magnetic Resonance Imaging Characterization of Acute Blood-Brain-Barrier Disruption Achieved with Intracranial Irreversible Electroporation”, PLOS One, Nov. 2012, 7:11, e50482.
Garcia, et al, A parametric study delineating irreversible electroporation from thermal damage based on a minimally invasive intracranial procedure, Biomedical Engineering Online, 2011, 10: 34, pp. 1-21.
Garcia, et al, Irreversible electroporation (IRE) to treat brain tumors, Proceedings of the ASME 2008 Summer Bioengineering Conference (SBC2008), Jun. 25, 2008, pp. 6-7.
McCarley, and Soulen, Percutaneous ablation of hepatic tumors, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 255-260.
McIntyre, C. C. et al., “Modeling the excitability of mammalian nerve fibers: Influence of afterpotentials on the recovery cycle,” J. Neurophysiol., vol. 87, No. 2, 995-1006, 2002, 12 pages.
McNeal, D. R., “Analysis of a Model for Excitation of Myelinated Nerve,” IEEE Trans. Biomed. Eng., vol. BME-23, No. 4 329-337, 1976, 9 pages.
McWilliams, et al, Image-guided tumor ablation: Emerging technologies and future directions, Seminars in Interventional Radiology, 2010, vol. 27, No. 3, pp. 302-313.
Mercadal, B. et al., “Avoiding nerve stimulation in irreversible electroporation: A numerical modeling study,” Phys. Med. Biol., vol. 62, No. 20, 8060-8079, 2017, 28 pages.
Miklav{hacek over (c)}i{hacek over (c)}, D. et al., “The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo or a potential use in clinical electrochemotherapy,” Bioelectrochemistry, vol. 65,121-128, 2004, 8 pages.
Min, M., A. Giannitsis, R. Land, B. Cahill, U. Pliquett, T. Nacke, D. Frense, G. Gastrock, and D. Beckmann, Comparison of rectangular wave excitations in broad band impedance spectroscopy for microfluidic applications, in World Congress on Medical Physics and Biomedical Engineering, Sep. 7-12, 2009, Munich, Germany. Springer, 2009, pp. 85-88.
Min, M., U. Pliquett, T. Nacke, A. Barthel, P. Annus, and R. Land, “Broadband excitation for short-time impedance spectroscopy,” Physiological measurement, vol. 29, No. 6, p. S185,2008.
Mir et al., “Mechanisms of Electrochemotherapy” Advanced Drug Delivery Reviews 35:107-118 (1999).
Mir et al., British Journal of Cancer, 77(12):2336-2342 (1998).
Mir, Chapter 1 application of electroporation gene therapy: Past, current and future, Electroporation Protocols: Preclinical and Clinical Gene Medicine, Methods in Molecular Biology, vol. 423, 2008, pp. 3-17.
Mir, Orlowski, Introduction: Electropermeabilization as a new drug delivery approach, Methods in Molecular Medicine, 2000, vol. 37, pp. 99-117.
Mulhall et al., “Cancer, pre-cancer and normal oral cells distinguished by dielectrophoresis.” Analytical and Bioanalytical Chemistry, vol. 401, pp. 2455-2463 (2011).
Nath, S., Dimarco, J. P. and Haines, D. E. (1994), Basic Aspects of Radiofrequency Catheter Ablation. Journal of Cardiovascular Electrophysiology, 5: 863-876.
Neal II, et al, Experimental characterization and numerical modeling of tissue electrical conductivity during pulsed electric fields for irreversible electroporation treatment planning, IEEE Transactions on Biomedical Engineering, Apr. 2012, vol. 59, No. 4, pp. 1076-1085.
Neal II, et al, Successful treatment of a large soft tissue sarcoma with irreversible electroporaiton, Journal of Clinical Oncology, May 1, 2011, vol. 29, No. 13, pp. e372-e377.
Neal II, R. E. et al. In Vitro and Numerical Support for Combinatorial Irreversible Electroporation and Electrochemotherapy Glioma Treatment. Annals of Biomedical Engineering, Oct. 29, 2013,13 pages.
Neal II, R.E., et al., “Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.” Breast Cancer Research and Treatment, 2010. 123(1): p. 295-301.
Neal II et al., “Experimental Characterization and Numerical Modeling of Tissue Electrical Conductivity during Pulsed Electric Fields for Irreversible Electroporation Treatment Planning,” Biomedical Engineering, IEEE Transactions on Biomedical Engineering, vol. 59, pp. 1076-1085, 2012.
Neal Re II, et al. (2013) Improved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Mice. PLoS One 8(5): e64559. https://doi.org/10.1371/journal.pone.0064559.
Neal, Davalos, The feasibility of irreversible electroporation for the treatment of breast cancer and other heterogeneous systems, Annals of Biomedical Engineering, Dec. 2009, vol. 37, No. 12, pp. 2615-2625.
Neal, et al, A study using irreversible electroporation to treat large, irregular tumors in a canine patient, 32nd Annual International Conference of the IEEE EMBS, IEEE, Aug. 2010, pp. 2747-2750.
Neal, et al, An “Off-the-Shelf” system for intraprocedural electrical current evaluation and monitoring of irreversible electroporation therapy, Cardiovasc Intervent Radiol, Feb. 27, 2014.
Nesin et al., “Manipulation of cell volume and membrane pore comparison following single cell permeabilization with 60- and 600-ns electric pulses.” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1808, pp. 792-801 (2011).
Neu, and Neu, Mechanism of irreversible electroporation in cells: Insight from the models, Irreversible Electroporation: Biomed, pp. 85-122.
Neven et al., Epicardial Linear Electroporation Ablation and Lesion Size, Department of Cardiology, University of Medical Utrecht, Aug. 2014, vol. 11, No. 8.
Nikolova, B., et al., “Treatment of Melanoma by Electroporation of Bacillus Calmette-Guerin”. Biotechnology & Biotechnological Equipment, 25(3): p. 2522-2524 (2011).
Nikolski, et al., Electroporation of the heart, Europace, 2005, 7, pp. S146-S154.
Nuccitelli, R., et al., “A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence”, Int J Cancer, 125(2): p. 438-445 (2009).
O'Brien, T. J. et al., “Effects of internal electrode cooling on irreversible electroporation using a perfused organ Model,” Int. J. Hyperth., vol. 35, No. 1, pp. 44-55, 2018.
O'Brien et al., “Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.” European Journal of Biochemistry, vol. 267, pp. 5421-5426 (2000).
Ohio Environmental Protection Agency, Ground Water Flow and Fate and Transport Modeling, State of Ohio Environmental Protection Agency, 2007, pp. 14-1-14-32.
Onik, and Rubinsky, Irreversible electroporation: First patient experience focal therapy of prostate cancer, Irreversible Electroporation, Biomed, pp. 235-247.
Onik, et al, Irreversible electroporation: Implications for prostate ablation, Technology in Cancer Research and Treatment, Aug. 2007, vol. 6, No. 4, pp. 295-300.
Onik, G. and B. Rubinsky, eds. “Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer. Irreversible Electroporation”, ed. B. Rubinsky 2010, Springer Berlin Heidelberg, pp. 235-247.
Onik, G.,P. Mikus, and B. Rubinsky, “Irreversible electroporation: implications for prostate ablation.” Technol Cancer Res Treat, 2007. 6(4): p. 295-300.
Ott, H. C., et al., “Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart”, Nature Medicine, Nature Publishing Group, New York, NY, US, vol. 14, No. 2,Feb. 1, 2008, pp. 213-221.
Pakhomova, O. N., Gregory, B., Semenov 1., and Pakhomov, A. G., BBA—Biomembr., 2014, 1838, 2547-2554.
Partridge, B. R. et al., “High-Frequency Irreversible Electroporation for treatment of Primary Liver Cancer: A Proof-of-Principle Study in Canine Hepatocellular Carcinoma,” J. Vasc. Interv. Radiol, vol. 31, No. 3, 482-491.e4, Mar. 2020, 19 pages.
Paszek et al., “Tensional homeostasis and the malignant phenotype.” Cancer Cell, vol. 8, pp. 241-254 (2005).
Pavseij, N. et al. The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. IEEE Trans Biomed Eng 52,1373-1381 (2005).
Pavselj, N., et al., “A numerical model of skin electroporation as a method to enhance gene transfection in skin. 11th Mediterranean Conference on Medical and Biological Engineering and Computing”, vols. 1 and 2, 16(1-2): p. 597-601 (2007).
PCT Application No. PCT/US 19/51731 (VTIP-A1001-PCT), International Search Report and Written Opinion dated Feb. 20, 2020,19 pgs.
PCT Application No. PCT/US09/62806, International Search Report (dated Jan. 19, 2010), Written Opinion (dated Jan. 19, 2010), and International Preliminary Report on Patentability (dated Jan. 4, 2010), 15 pgs.
PCT Application No. PCT/US10/53077, International Search Report (dated Aug. 2, 2011), Written Opinion (dated Aug. 2, 2011), and International Preliminary Report on Patentability (dated Apr. 17, 2012).
PCT Application No. PCT/US15/30429 (VTIP-97), International Search Report and Written Opinion dated Oct. 16, 2015,19 pages.
PCT Application No. PCT/US15/65792, International Search Report (dated Feb. 9, 2016), Written Opinion (dated Feb. 9, 2016), and International Preliminary Report on Patentability (dated Jun. 20, 2017), 15 pages.
PCT Application No. PCT/US2004/043477, International Search Report (dated Aug. 26, 2005), Written Opinion (dated Aug. 26, 2005), and International Preliminary Report on Patentability (dated Jun. 26, 2006).
PCT Application No. PCT/US2009/042100, International Search Report (dated Jul. 9, 2009), Written Opinion (dated Jul. 9, 2009), and International Preliminary Report on Patentability (dated Nov. 2, 2010).
PCT Application No. PCT/US2010/030629, International Search Report (dated Jul. 15, 2010), Written Opinion (dated Jul. 15, 2010), and International Preliminary Report on Patentability (dated Oct. 11, 2011).
Garcia, et al, Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient, Feb. 2011, vol. 10, No. 1, pp. 73-83.
Garcia, et al, Non-thermal irreversible electroporation for deep intracranial disorders, 32nd Annual International Conference of the IEEE EMBS, IEEE, Aug. 2010, pp. 2747463.
Garcia, et al, Position paper concerning the use of Angiodynamics' nanoknife system for treatment of brain gliomas, Virgina Tech—Wake Forest University, May 22, 2013, pp. 1-46.
Garcia, P.A., et al., Intracranial Nonthermal Irreversible Electroporation: In Vivo Analysis. Journal of Membrane Biology, 2010. 236(1): p. 127-136.
Garcia, P.A., R.V. Davalos, and D. Miklavcic, A Numerical Investigation of the Electric and Thermal Cell Kill Distributions in Electroporation-Based Therapies in Tissue. Plos One, 2014. 9(8).
Garcia, Paulo A., Robert E. Neal IL and Rafael V. Davalos, Chapter 3, Non-Thermal Irreversible Electroporation for Tissue Ablation, In: Electroporation in Laboratory and Clinical Investigations ISBN 978-1-61668-327-6 Editors: Enrico P. Spugnini and Alfonso Baldi, 2010,22 pages.
Gascoyne et al., “Membrane changes accompanying the induced differentiation of Friend murine erythroleukemia cells studied by dielectrophoresis.” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1149, pp. 119-126 (1993).
Gawad, S., T. Sun, N. G. Green, and H. Morgan, “Impedance spectroscopy using maximum length sequences: Application to single cell analysis,” Review of Scientific Instruments, vol. 78, No. 5, p. 054301,2007.
Gilbert, T. W., et al., “Decellularization of tissues and organs”, Biomaterials, Elsevier Science Publishers, Barking, GB, vol. 27, No. 19, Jul. 1, 2006, pp. 3675-3683.
Gimsa, et al, Dielectric spectroscopy of single human erythrocytes at physiological ionic strength: Dispersion of the cytoplasm, Biophysical Journal, Jul. 1996, vol. 71, pp. 495-506.
Golberg, A. and Rubinsky, B., “A statistical model for multidimensional irreversible electroporation cell death in tissue.” Biomed Eng Online, 9,13 pages, 2010.
Gowrishankar et al., An Approach to electrical modeling of single and multiple cells, Mar. 18, 2003, PNAS, vol. 100 No. 6, pp. 3203-3208.
Gowrishankar T.R., et al., “Microdosimetry for conventional and supra-electroporation in cells with organelles”. Biochem Biophys Res Commun, 341(4): p. 1266-76 (2006).
Granot, Y., A. Ivorra, E. Maor, and B. Rubinsky, “In vivo imaging of irreversible electroporation by means of electrical impedance tomography,” Physics in Medicine & Biology, vol. 54, No. 16, p. 4927,2009.
Groen, M. H. A. et al., “In Vivo Analysis of the Origin and Characteristics of Gaseous Microemboli during Catheter-Mediated Irreversible Electroporation,” Europace, 2021, 23(1), 139-146.
Guenther, E. et al., “Electrical breakdown in tissue electroporation,” Biochem. Biophys. Res. Commun., vol. 467, No. 4, 736-741, Nov. 2015, 15 pages.
Guo, et al, Irreversible electroporation in the liver: Contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones, Radiology, Feb. 2011, vol. 258, No. 2, pp. 461-468.
Hall, et al, Nanosecond pulsed electric fields have differential effects on cells in the S-phase, DNA and Cell Biology, 2007, vol. 26, No. 3, pp. 160-171.
Hall, et al, Nanosecond pulsed electric fields induce apoptosis in p53-wildtype and p53-null HCT116 colon carcinoma cells, Apoptosis, May 23, 2007, 12, pp. 1721-1731.
Hasgall, P. et al., “IT'IS Database for thermal and electromagnetic parameters of biological tissues,” 2018, it is.swiss/database%0A%0A.
He, et al, Nonlinear current response of micro electroporation and resealing dynamics for human cancer cells, Bioelectrochemistry, Jan. 29, 2008, 72, pp. 161-168.
Helczynska et al., “Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.” Cancer Research, vol. 63, pp. 1441-1444 (2003).
Hjouj, et al, MRI study on reversible and irreversible electroporation induced blood brain barrier disruption, Aug. 10, 2012, PLOS One, vol. 7, 8, e42817, pp. 1-9.
Hjouj, M., et al., “MRI Study on Reversible and Irreversible Electroporation Induced Blood Brain Barrier Disruption”, PLOS One, Aug. 2012, 7:8, e42817.
Hjouj, Mohammad et al., “Electroporation-Induced BBB Disruption and Tissue Damage Depicted by MRI,” Abstracts from 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, Nov. 17-20, 2011, Orange County California, Neuro-Oncology Supplement, vol. 13, Supplement 3, p. iii114.
Hoejholt, K. L. et al. Calcium electroporation and electrochemotherapy for cancer treatment: Importance of cell Tiembrane composition investigated by lipidomics, calorimetry and in vitro efficacy. Scientific Reports (Mar. 18, 2019) 3:4758, p. 1-12.
Hong, et al, Cardiac ablation via electroporation, 31st Annual International Conference of the IEEE EMBS, IEEE, Sep. 2, 2009, pp. 3381-3384.
Hu, Q., et al., “Simulations of transient membrane behavior in cells subjected to a high-intensity ultrashort electric pulse”, Physical Review E, 71(3) (2005).
Ibey et al., “Selective cytotoxicity of intense nanosecond-duration electric pulses in mammalian cells.” Biochimica Et Biophysica Acta—General Subjects, vol. 1800, pp. 1210-1219 (2010).
International Application No. PCT/US2009/042100, International Search Report dated Jul. 9, 2009, 5 pages.
International Search Report 06751655_SESR dated Oct. 16, 2009.
International Search Report 07716249_SESR dated Jan. 19, 2009.
International Search Report 09739678_SESR dated May 3, 2012.
International Search Report 12002108_EPS dated May 30, 2012.
International Search Report 12002108.4 ESO dated Jun. 12, 2013.
International Search Report for 06751655 SESR dated Oct. 9, 2016.
International Search Report for 06751655.9 ESO dated Oct. 29, 2009.
International Search Report for 10824248.8 ESO dated Jan. 20, 2014.
International Search Report for 11833421 SESR dated Mar. 18, 2014.
International Search Report for IPRP, PCT/US2006/01645, dated Oct. 30, 2007, 5 pages.
International Search Report for PCT-US-10-053077 ISR dated Aug. 2, 2011.
International Search Report for PCT-US-10-053077 WOSA dated Aug. 2, 2011.
International Search Report for PCT/US06/16045 ISR dated Sep. 25, 2007, 1 page.
International Search Report for PCT/US2006/016045 IPRP dated Oct. 30, 2007.
International Search Report for PCT/US2007/000084 IPRP dated Jul. 8, 2008, 8 pages.
International Search Report for PCT/US2009/038661 IPRP dated Sep. 28, 2010.
International Search Report for PCT/US2009/042100 IPRP dated Nov. 2, 2010.
International Search Report for PCT/US2009/042100 WOSA dated Jul. 9, 2009.
International Search Report for PCT/US2009/047969 IPRP dated Dec. 21, 2010.
International Search Report for PCT/US2009/047969 ISR dated Jan. 21, 2010.
International Search Report for PCT/US2009/047969 WOSA dated Jan. 21, 2010.
International Search Report for PCT/US2009/048270 IPRP dated Jan. 5, 2011.
International Search Report for PCT/US2009/048270 ISR dated Feb. 11, 2010.
International Search Report for PCT/US2009/048270 WOSA dated Feb. 11, 2010.
International Search Report for PCT/US2009/062806 WOSA dated Jan. 19, 2010.
International Search Report for PCT/US2010/022011 IPRP dated Jul. 26, 2011.
International Search Report for PCT/US2010/022011 ISR dated Aug. 30, 2010.
International Search Report for PCT/US2010/022011 WOSA dated Aug. 30, 2010.
International Search Report for PCT/US2010/029243 IPRP dated Oct. 4, 2011.
International Search Report for PCT/US2010/029243 WOSA dated Jul. 30, 2010.
International Search Report for PCT/US2010/036734 IPRP dated Nov. 29, 2011.
International Search Report for PCT/US2010/036734 ISR dated Dec. 23, 2010.
International Search Report for PCT/US2010/036734 WOSA dated Dec. 23, 2010.
International Search Report for PCT/US2010/053077 IPRP dated Apr. 17, 2012.
International Search Report for PCT/US2011/024909 IPRP dated Aug. 21, 2012.
International Search Report for PCT/US2011/024909 ISR dated Oct. 18, 2011.
International Search Report for PCT/US2011/024909 WOSA dated Oct. 18, 2011.
International Search Report for PCT/US2011/025003 IPRP dated Aug. 21, 2012.
International Search Report for PCT/US2011/025003 ISR dated Oct. 24, 2011. 10 pages.
International Search Report for PCT/US2011/025003 WOSA dated Oct. 24, 2011.
International Search Report for PCT/US2011/056177 ESO dated Mar. 28, 2014.
International Search Report for PCT/US2011/056177 IPRP dated Apr. 16, 2013.
International Search Report for PCT/US2011/056177 ISR dated May 30, 2012.
International Search Report for PCT/US2011/056177 WOSA dated May 30, 2012.
International Search Report for PCT/US2011/062067 IPRP dated May 28, 2013.
International Search Report for PCT/US2011/062067 ISR dated Jul. 25, 2012.
International Search Report for PCT/US2011/062067 WOSA dated Jul. 25, 2012.
International Search Report for PCT/US2015/065792 dated Feb. 9, 2016.
International Search Report PCT-US-07-000084 ISR dated Dec. 14, 2007, 2 pages.
International Search Report PCT/US07/00084 WOSA dated Dec. 14, 2007, 7 pages.
International Search Report PCT/US2009/038661 ISR dated Jun. 12, 2009.
International Search Report PCT/US2009042100 ESO dated May 11, 2012.
Issa, et al, Recent Reports: The TUNA procedure for BPH: Review of the technology, Infections in Urology, Jul. 1998, 8 pages.
Issa, et al, Specialty Surgery: The TUNA procedure for BPH: Basic procedure and clinical results, Infections in Urology, Sep. 1998, 6 pages.
Ivey, J_ W., E. L. Latouche, M. B. Sano, J_ H. Rossmeisl, R. V. Davalos, and S. S. Verbridge, “Targeted cellular ablation based on the morphology of malignant cells,” Sci. Rep., vol. 5, pp. 1-17, 2015.
Ivorra et al., “In vivo electric impedance measurements during and after electroporation of rat live.” Bioelectrochemistry, vol. 70, pp. 287-295 (2007).
Ivorra, et al, In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome,Phys. Med. Biol., Sep. 17, 2009, 54, pp. 5949-5963.
Ivorra, et al., Impedance analyzer for in vivo electroporation studies, Proceedings of the 28th IEEE EMBS Annual International Conference, IEEE, Aug. 30, 2006, pp. 5056-5059.
Ivorra,“Bioimpedance monitoring for physicians: an overview.” Biomedical Applications Group, 35 pages (2002).
Jan Ko et al, “New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins”, Brain Research Bulletin, Elsevier Science Ltd, Oxford, GB, (Oct. 1, 2001), vol. 56, No. 3-4, doi:10.1016/S0361-9230(01)00599-8, ISSN 0361-9230, pp. 319-329, XP002509144.
Jarm et al., “Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases.” Expert Rev Anticancer Ther. vol. 10, pp. 729-746 (2010).
Jensen et al., “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18FFDG-microPET or external caliper.” BMC medical Imaging vol. 8:16, 9 Pages 2008).
Jiang, et al, Membrane-targeting approaches for enhanced cancer cell destruction with irreversible electroporation, Annuals of Biomedical Engineering, Aug. 15, 2013.
Jordan, D.W., et al., “Effect of pulsed, high-power radiofrequency radiation on electroporation of mammalian cells”, Ieee Transactions on Plasma Science, 32(4): p. 1573-1578 (2004).
Jossinet et al., Electrical Impedance Endo-Tomography: Imaging Tissue From Inside, IEEE Transactions on Medical Imaging, vol. 21, No. 6, Jun. 2002, pp. 560-565.
Kanduser, et al, Cell membrane fluidity related to electroporation and resealing, Eur Biophys J, Oct. 8, 2006, 35, pp. 196-204.
Katsuki, S., et al., “Biological effects of narrow band pulsed electric fields”, Ieee Transactions on Dielectrics and Electrical Insulation,. 14(3): p. 663-668 (2007).
Kingham et al., “Ablation of perivascular hepatic malignant tumors with irreversible electroporation.” Journal of the American College of Surgeons, 2012. 215(3), p. 379-387.
Kinosita et al., “Electroporation of cell membrane visualized under a pulsed-laser fluorescence microscope.” Biophysical Journal, vol. 53, pp. 1015-1019 (1988).
Kinosita et al., “Voltage-induced pore formation and hemolysis of human erythrocytes.” Biochimica et Biophysica Acta (BBA)—Biomembranes, 471 (1977) pp. 227-242.
Alberts et al., “Molecular Biology of the Cell,” 3rd edition, Garland Science, New York, 1994, 1 page.
Bagla, Papadouris, Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: A case report, J Vasc Interv Radiol, 2012, 23, pp. 142-145.
Blad, et al., Impedance Spectra of Tumour Tissue in Comparison with Normal Tissue; a Possible Clinical Application for Electrical Impedance Tomography, Physiol. Meas. 17 (1996) A105-A115.
Boone, K., Barber, D. & Brown, B. Review—Imaging with electricity: report of the European Concerted Action on Impedance Tomography. J. Med. Eng. Technol. 21, 201-232 (1997).
BPH Management Strategies: Improving Patient Satisfaction, Urology Times, May 2001, vol. 29, Supplement 1. 22 pages.
Duraiswami, et al., Solution of Electrical Impedance Tomography Equations Using Boundary Element Methods, Boundary Element Technology XU, 1997, pp. 226-237.
Edd et al., “Mathematical modeling of irreversible electroporation for treatment planning.” Technology in Cancer 20 Research and Treatment, vol. 6, No. 4, pp. 275-286 (2007).
Edd, J., et al., In-Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporaton, IEEE Trans. 21 Biomed. Eng. 53 (2006) p. 1409-1415.
Faroja, M., et al., “Irreversible Electroporation Ablation: Is the entire Damage Nonthermal?”, Radiology, 266(2), 28 462-470 (2013).
Garcia, et al., “A Parametric Study Delineating Irreversible Electroporation from Thermal Damage Based on a 40 Minimally Invasive Intracranial Procedure,” Biomed Eng Online, vol. 10:34, 22 pages, 2011.
Garcia, P. A., et al., “Towards a predictive model of electroporation-based therapies using pre-pulse electrical 41 measurements,” Conf Proc IEEE Eng Med Biol Soc, vol. 2012, pp. 2575-2578, 2012.
Garcia, P. A., et al., “Non-thermal Irreversible Electroporation (N-TIRE) and Adjuvant Fractioned Radiotherapeutic Multimodal Therapy for Intracranial Malignant Glioma in a Canine Patient” Technol. Cancer Res. Treatment 10(1), 73-83 (2011).
Glidewell, et al., The Use of Magnetic Resonance Imaging Data and the Inclusion of Anisotropic Regions in Electrical Impedance Tomography, Biomed, Sci. Instrum. 1993; 29: 251-7.
Griffiths, Tissue Spectroscopy with Electrical Impedance Tomography: Computer Simulations, IEEE Transactions on Biomedical Engineering, vol. 42, No. 9, Sep. 1995. 8 pages.
Gumerov, et al, The dipole approximation method and its coupling with the regular boundar yelement method for efficient electrical impedance tomography, BETECH Jun. 1999.
Huang, Rubinsky, Micro-electroporation: improving the efficiency and understanding of electrical permeabilization of cells, Biomedical Microdevices, 1999, 2:2, pp. 145-150.
Latouche, E. L., M. B. Sano, M. F. Lorenzo, R. V. Davalos, and R. C. G. Martin, “Irreversible electroporation for the ablation of pancreatic malignancies: A patient-specific methodology,” J. Surg. Oncol., vol. 115, No. 6, pp. 711-717, 2017.
Lee, E.W., et al., “Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation”, Technol Cancer Res Treat 6: 287-294 (2007).
Li, W., et al., “The Effects of Irreversible Electroporation (IRE) on Nerves” PloS One, Apr. 2011, 6(4), e18831. 7 pages.
Mercadal, Borja et al. “Dynamics of Cell Death After Conventional IRE and H-FIRE Treatments”, Annals of Biomedical Engineering, vol. 48, No. 5, 2020, p. 1451-1462.
Naslund, Cost-Effectiveness of Minimally Invasive Treatments and Transurethral Resection (TURP) in Benign Prostatic Hyperplasia (BPH), (Abstract), Presented at 2001 AUA National Meeting,, Anaheim, CA, Jun. 5, 2001. 1 page.
Neal II et al., “A Case Report on the Successful Treatment of a Large Soft-Tissue Sarcoma with Irreversible Electroporation,” Journal of Clinical Oncology, 29, pp. 1-6, 2011.
Neal II, R. E., et al., “Successful Treatment of a Large Soft Tissue Sarcoma with Irreversible Electroporation”, Journal of Clinical Oncology, 29:13, e372-e377 (2011).
Neal II, Robert E. and R.V. Davalos, The Feasibility of Irreversible Electroporation for the Treatment of Breast Cancer and Other Heterogeneous Systems, Ann Biomed Eng, 2009, 37(12): p. 2615-2625.
PCT Application No. PCT/2011/062067, International Preliminary Report on Patentability dated May 28, 2013. 7 pages.
PCT Application No. PCT/2011/066239, International Preliminary Report on Patentability dated Jun. 25, 2013. 7 pages.
PCT Application No. PCT/US15/30429, International Report on Patentability dated Nov. 15, 2016. 7 pages.
PCT Application No. PCT/US19/51731 (VTIP-A1001-PCT), International Preliminary Report on Patentability dated Mar. 23, 2021, 13 pages.
Pending Application No. PCT/US21/51551 (VTIP-A1018-PCT), International Search Report and Written Opinion dated Dec. 29, 2021, 14 pages.
Pending Application No. PCT/US23/15118 (VTIP-A1023-PCT), International Search Report and Written Opinion dated Jul. 31, 2023, 18 pages.
Phillips, M., Maor, E. & Rubinsky, B. Nonthermal Irreversible Electroporation for Tissue Decellularization. J. Biomech. Eng, doi: :10.1115/1.4001882 (2010). 8 pages.
Polak et al., “On the Electroporation Thresholds of Lipid Bilayers: Molecular Dynamics Simulation Investigations.” The Journal of Membrane Biology, vol. 246, pp. 843-850 (2013).
Rebersek, M. and D. Miklav, “Advantages and Disadvantages of Different Concepts of Electroporation Pulse Generation,” Automatika 52(2011) 1, 12-19.
Thomson et al., “Investigation of the safety of irreversible electroporation in humans,” J Vasc Interv Radiol, 22, pp. 611-621, 2011.
TUNA—Suggested Local Anesthesia Guidelines, no date available. 1 page.
Precision Office TUNA System, “When Patient Satisfaction is Your Goal.” Product Literature Published by VidaMed, Inc., 11 pages (2001).
Related Publications (1)
Number Date Country
20210369325 A1 Dec 2021 US
Provisional Applications (1)
Number Date Country
61392905 Oct 2010 US
Continuations (3)
Number Date Country
Parent 16222319 Dec 2018 US
Child 17346733 US
Parent 15612006 Jun 2017 US
Child 16222319 US
Parent 13273001 Oct 2011 US
Child 15612006 US